**Targeted Inhibition of Multiple Proinflammatory Signalling Pathways for the Prevention and Treatment of Multiple Myeloma**

Radhamani Kannaiyan1, Rohit Surana1,2, Eun Myoung Shin2, Lalitha Ramachandran1, Gautam Sethi1,2,\* and Alan Prem Kumar1,2,3,\* *1Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, 2Cancer Science Institute of Singapore, National University of Singapore, 3School of Anatomy and Human Biology, The University of Western Australia, Crawley, Perth, Western Australia 1,2Singapore 3Australia*

#### **1. Introduction**

92 Multiple Myeloma – An Overview

Tucci M, Stucci S, Strippoli S, et al. (2011). Dendritic Cells and Malignant Plasma Cells: An Alliance in Multiple Myeloma Tumor Progression? *Oncologist,* 16(7): 1040-1048 van Rhee F, Szmania SM, Zhan F, et al. (2005). NY-ESO-1 is highly expressed in poor-

Vasir B, Borges V, Wu Z, et al. (2005). Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation. *Br J Haematol,* 129(5), 687-700 Vonderheide RH, Hahn WC, Schultze JL, et al. (1999). The telomerase catalytic subunit is a

Wang S, Hong S, Yang J, et al. (2006). Optimizing immunotherapy in multiple myeloma:

Wang S, Yang J, Qian J, et al. (2006). Tumor evasion of the immune system: inhibiting p38

Wen YJ, Ling M, Bailey-Wood R, et al. (1998). Idiotypic protein-pulsed adherent peripheral

Wen YJ, Barlogie B, Yi Q. (2001). Idiotype-specific cytotoxic T lymphocytes in multiple

Wen YJ, Min R, Tricot G, et al. (2002). Tumor lysate-specific cytotoxic T lymphocytes in

Yamazaki S, Inaba K, Tarbell KV, et al. (2006). Dendritic cells expand antigen-specific

Yang DH, Kim MH, Hong CY, et al. (2010). Alpha-type 1-polarized dendritic cells loaded

Yang DH, Kim MH, Lee YK, et al. (2011) Successful cross-presentation of allogeneic

Yang DH, Park JS, Jin CJ, et al. (2009). The dysfunction and abnormal signaling pathway of

Yi Q, Szmania S, Freeman J, et al. (2010). Optimizing dendritic cell-based immunotherapy in

Yi Q, Desikan R, Barlogie B, et al. (2002). Optimizing dendritic cell-based immunotherapy in

Yu H, Kortylewski M, Pardoll D. (2007). Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. *Nat Rev Immunol,* 7(1), 41-51 Zou W. (2005). Immunosuppressive networks in the tumour environment and their

autologous myeloma cells. *Ann Hematol,* 89(8):795-801

*Ann Hematol,* Apr 5. [Epub ahead of print]

multiple myeloma. *Leuk Res,* 33(5), 665-670

multiple myeloma. *Br J Haematol,* 117(2), 297-305

therapeutic relevance. *Nat Rev Cancer,* 5(4), 263-274

patients. *Br J Haematol,* 150(5), 554-564

immune responses. *Blood,* 105(10), 3939-3944

*Immunity,* 10(6), 673-679

107(6), 2432-2439

97(6), 1750-1755

*Immunol Rev,* 212, 314-329

3285

cells. *Blood,* 108(13), 4071-4077

myeloma. *Clin Cancer Res,* 4(4), 957-962

prognosis multiple myeloma and induces spontaneous humoral and cellular

widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes.

Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor

MAPK signaling restores the function of dendritic cells in multiple myeloma. *Blood,*

blood mononuclear cell-derived dendritic cells prime immune system in multiple

myeloma: evidence for their capacity to lyse autologous primary tumor cells. *Blood,*

multiple myeloma: promising effector cells for immunotherapy. *Blood,* 99(9), 3280-

Foxp3+ CD25+ CD4+ regulatory T cells including suppressors of alloreactivity.

with apoptotic allogeneic myeloma cell line induce strong CTL responses against

myeloma cells by autologous alpha-type 1-polarized dendritic cells as an effective tumor antigen in myeloma patients with matched monoclonal immunoglobulins.

dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in

multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in Multiple myeloma (MM) is a B cell malignancy involving the post germinal centre B cells. The disease is characterized by the presence of blood and urinary monoclonal proteins, osteolytic bone lesions and infiltration of bone marrow with malignant plasma cells of low proliferative index. Multiple myeloma is mainly a disease of elderly males, but, there is evidence to support that there is increasing incidence in younger individuals as well. American blacks are more prone than American whites. MM is the most common non Hodgkin's haematological malignancy, contributing 13% of all malignancies and 1% of all neoplasias. The median survival is 3-4 years, but with autologous stem cell transplantation and high dose chemotherapy, the median survival has increased to 5-7 years [1].

Most, if not all, multiple myeloma evolve from a premalignant condition known as 'Multiple Gammapathy of Undetermined Significance (MGUS)'. It then progresses via a 'smouldering multiple myeloma' stage, to a full blown disease and finally to an 'extramedullary MM' condition, where the malignant cells are no longer dependent on the bone marrow microenvironment for their proliferation. On a cellular scale, the origin of MM is thought to be post germinal centre B cell or memory B cell, indicated by the presence of hypermutated immunoglobulin gene. Evidence also supports the stem cell origin of the disease, as indicated by activated Wnt and Hedgehog signalling in the subset of cells in MM primary samples [2].

Cornelius Celsus, a Roman physician, first described the features of inflammation (inflammation - to set on fire) with the following signs: heat (calor), pain (dolour), redness (rubor) and swelling (tumour). The main purpose of inflammation is to protect the host

<sup>\*</sup> Corresponding Authors

Targeted Inhibition of Multiple Proinflammatory

Signalling Pathways for the Prevention and Treatment of Multiple Myeloma 95

The stromal derived factor (SDF/CXCL12), secreted by the bone marrow stromal cells, plays an important role in the homing of MM cells to the bone marrow, which expresses receptor CXCR4. Moreover, adhesion of MM cells to stromal cells or fibronectin, induces chemoresistance in MM cells, mediated by integrins [11]. The adhesion molecules namely, very late antigen (VLA-4), vascular cell adhesion molecule (VCAM-1) and lymphocyte function–associated antigen 1 (LFA-1), intercellular adhesion molecule (ICAM–1), mediate integrin induced chemoresistance [12]. The resistance is mediated partly due to the activation of NF-κB, which upregulates anti-apoptotic gene products. MM samples are found to have various mutations activating both classical and alternative NF-κB. Apart from the mutations, the NF-κB pathway can also be stimulated by B cell growth factors like BAF

Adhesion of MM cells to the stromal cells, induces the latter to secrete IL-6. IL-6 is the main growth factor for the MM cells. IL-6 then induces JAK/STAT 3, PI3/AKT and MAPK survival pathways. STAT 3 transcription factor upregulates its targets, namely, cyclin D1 and Mcl-1, which promote cell proliferation and antiapoptosis respectively. In addition to the IL-6 induced activation of STAT 3, DNA methylation is found to silence the negative regulators of STAT 3. On the other hand, IGF secreted by bone marrow stromal cells induces PI3/AKT pathways [14]. AKT promotes cell proliferation by phosphorilating GSK3β, which regulates cyclin D1 proteolysis. Activated MAPK pathway leads to the activation of ERK, promoting MM growth and survival [15]. The following section will elaborate on the very

Interleukin-6, a pleotropic cytokine, is involved in processes such as haematopoiesis, immunity and inflammation. It was discovered as a factor secreted from mitogen stimulated T cells, which helps mature B cells transform into antibody producing plasma cells [16]. Because of its pleotropic nature, various laboratories were working with its different functions, giving it different names: B cell stimulating factor II (BSF II) as it stimulated B cells to turn into plasma cells and secrete antibodies, interferon-ß2 [17] as it was thought to have the properties of interferon but later it was proven that IL-6 does not have properties of interferon, 26 kDa protein - named after its molecular weight, a hybridoma/plasmacytoma growth factor as it induced plasmacytoma in balb/c mice injected with mineral oil [18] and a hepatocyte-stimulating factor as it stimulated

IL-6 binds to its receptor, which is either membrane bound or in soluble form. It then activates ubiquitously expressed receptor gp130 [20]. Once gp130 gets activated, IL-6 acts by three of the following signalling pathways: JAK-STAT pathway, MAPK-ERK and PI3-AKT pathway. Most of the actions of IL-6 are executed by JAK-STAT pathway [21]. IL-6 is found to be involved in the growth of many solid tumours like prostate cancer and renal cancer. Pathogenesis of Kaposi sarcoma has been proven to be due to the secretion of IL-6 [22-24].

IL-6 is one of the main growth factors in multiple myeloma [25]. In fact, IL-6 knock out mice failed to develop MM [26]. Moreover, the serum level of IL-6 and soluble IL-6 receptor has

IL-6 is also involved in the growth of many haematological malignancies.

and APRIL, which are secreted by the bone marrow microenvironment [13].

common and important inflammatory player, involved in the progression of MM.

**2. Role of proinflammatory cytokines and growth factors** 

hepatocytes to produce acute phase proteins [19].

**2.1 Interleukin - 6** 

organism from the microbes and other noxious stimuli. However, when the infection cannot be controlled or when there is a constant presence of the damaging stimuli, inflammatory process gets deregulated, resulting in a condition called chronic inflammation, which is destructive to the host organism. Thus inflammation is aptly termed as a 'double edged sword'. The link between inflammation and cancer was first established in 1897, by a German pathologist named Dr. Rudolf Virchow. He found that leukocytes infiltrate tumour tissue and therefore, termed tumours as 'wounds that do not heal'. Since then there has been much evidence to link inflammation and cancer, so as to be able to add inflammation as one of the hallmarks of cancer [3-5].

In the linking of inflammation and cancer, two pathways are said to exist - extrinsic and intrinsic. In the extrinsic pathway, chronic inflammation leads to autoimmune diseases, which eventually culminate in cancer. For example, H.pylori infection in the stomach, Hepatitis B and Hepatitis C infections in the liver, inflammatory bowel diseases and inflammation of the prostate gland (prostatitis); lead to incidences of gastric cancer, hepatocarcinoma, colon cancer and prostate cancer, respectively. In fact, about 20% of all cancers are said to arise in an inflammatory environment. In the intrinsic pathway, activation of oncogenes or inactivation of the tumour suppressor genes, causing both cancer and inflammation, which complement each other [6, 7]. Irrespective of the pathways involved, the perpetrators of the cancer related inflammation are inflammatory cells and inflammatory mediators, such as cytokines, chemokines, growth factors, all of which finally converge on a few transcription factors [8]. Not surprisingly, agents modulating cancerrelated inflammation have been tried in cancer therapeutics [9].

MM cells depend largely on a bone marrow microenvironment for their growth and survival, until the last stage of the disease, where they invade other areas to be termed as extramedullary MM. The bone marrow microenvironment can be broadly divided into cellular and non-cellular components. Cellular components include myeloma cells, bone marrow stromal cells or bone marrow fibroblasts, haematopoietic precursor cells, osteoclasts, osteoblasts, endothelial cells and immune cells. Of these, the supportive role of stromal cells in MM has been studied extensively. The interactions between myeloma cells and osteoclasts have also been studied to an extent. The bone marrow stromal cells and osteoclasts provide the myeloma cells with the ability to grow and survive, either by direct adhesion and/or by secreting growth and survival cytokines.

The non-cellular compartment is comprised of the extracellular matrix and the soluble factors. Extracellular matrix consists of various proteins like collagen, fibronectin and laminin. The extracellular matrix not only acts as depots for the growth factors, but also provides the myeloma cells with the ability to resist cell death induced by chemotherapeutic agents. The survival advantage offered by the bone marrow microenvironment to the MM cells is achieved by 1. the soluble growth factors which are secreted by various cellular components, 2. insoluble growth factors that are bound to the extracellular matrix component and 3. adhesion molecules that help MM cells adhere to the extracellular matrix and the cellular compartment. In fact, in a recent study, 22 out of the 51 multiple myeloma growth factor genes that could be interrogated by affymetrix were found to be significantly overexpressed by at least one bone marrow environment population compared to others [10].

The stromal derived factor (SDF/CXCL12), secreted by the bone marrow stromal cells, plays an important role in the homing of MM cells to the bone marrow, which expresses receptor CXCR4. Moreover, adhesion of MM cells to stromal cells or fibronectin, induces chemoresistance in MM cells, mediated by integrins [11]. The adhesion molecules namely, very late antigen (VLA-4), vascular cell adhesion molecule (VCAM-1) and lymphocyte function–associated antigen 1 (LFA-1), intercellular adhesion molecule (ICAM–1), mediate integrin induced chemoresistance [12]. The resistance is mediated partly due to the activation of NF-κB, which upregulates anti-apoptotic gene products. MM samples are found to have various mutations activating both classical and alternative NF-κB. Apart from the mutations, the NF-κB pathway can also be stimulated by B cell growth factors like BAF and APRIL, which are secreted by the bone marrow microenvironment [13].

Adhesion of MM cells to the stromal cells, induces the latter to secrete IL-6. IL-6 is the main growth factor for the MM cells. IL-6 then induces JAK/STAT 3, PI3/AKT and MAPK survival pathways. STAT 3 transcription factor upregulates its targets, namely, cyclin D1 and Mcl-1, which promote cell proliferation and antiapoptosis respectively. In addition to the IL-6 induced activation of STAT 3, DNA methylation is found to silence the negative regulators of STAT 3. On the other hand, IGF secreted by bone marrow stromal cells induces PI3/AKT pathways [14]. AKT promotes cell proliferation by phosphorilating GSK3β, which regulates cyclin D1 proteolysis. Activated MAPK pathway leads to the activation of ERK, promoting MM growth and survival [15]. The following section will elaborate on the very common and important inflammatory player, involved in the progression of MM.

#### **2. Role of proinflammatory cytokines and growth factors**

#### **2.1 Interleukin - 6**

94 Multiple Myeloma – An Overview

organism from the microbes and other noxious stimuli. However, when the infection cannot be controlled or when there is a constant presence of the damaging stimuli, inflammatory process gets deregulated, resulting in a condition called chronic inflammation, which is destructive to the host organism. Thus inflammation is aptly termed as a 'double edged sword'. The link between inflammation and cancer was first established in 1897, by a German pathologist named Dr. Rudolf Virchow. He found that leukocytes infiltrate tumour tissue and therefore, termed tumours as 'wounds that do not heal'. Since then there has been much evidence to link inflammation and cancer, so as to be able to add inflammation as one

In the linking of inflammation and cancer, two pathways are said to exist - extrinsic and intrinsic. In the extrinsic pathway, chronic inflammation leads to autoimmune diseases, which eventually culminate in cancer. For example, H.pylori infection in the stomach, Hepatitis B and Hepatitis C infections in the liver, inflammatory bowel diseases and inflammation of the prostate gland (prostatitis); lead to incidences of gastric cancer, hepatocarcinoma, colon cancer and prostate cancer, respectively. In fact, about 20% of all cancers are said to arise in an inflammatory environment. In the intrinsic pathway, activation of oncogenes or inactivation of the tumour suppressor genes, causing both cancer and inflammation, which complement each other [6, 7]. Irrespective of the pathways involved, the perpetrators of the cancer related inflammation are inflammatory cells and inflammatory mediators, such as cytokines, chemokines, growth factors, all of which finally converge on a few transcription factors [8]. Not surprisingly, agents modulating cancer-

MM cells depend largely on a bone marrow microenvironment for their growth and survival, until the last stage of the disease, where they invade other areas to be termed as extramedullary MM. The bone marrow microenvironment can be broadly divided into cellular and non-cellular components. Cellular components include myeloma cells, bone marrow stromal cells or bone marrow fibroblasts, haematopoietic precursor cells, osteoclasts, osteoblasts, endothelial cells and immune cells. Of these, the supportive role of stromal cells in MM has been studied extensively. The interactions between myeloma cells and osteoclasts have also been studied to an extent. The bone marrow stromal cells and osteoclasts provide the myeloma cells with the ability to grow and survive, either by direct

The non-cellular compartment is comprised of the extracellular matrix and the soluble factors. Extracellular matrix consists of various proteins like collagen, fibronectin and laminin. The extracellular matrix not only acts as depots for the growth factors, but also provides the myeloma cells with the ability to resist cell death induced by chemotherapeutic agents. The survival advantage offered by the bone marrow microenvironment to the MM cells is achieved by 1. the soluble growth factors which are secreted by various cellular components, 2. insoluble growth factors that are bound to the extracellular matrix component and 3. adhesion molecules that help MM cells adhere to the extracellular matrix and the cellular compartment. In fact, in a recent study, 22 out of the 51 multiple myeloma growth factor genes that could be interrogated by affymetrix were found to be significantly overexpressed by at least one bone marrow environment

related inflammation have been tried in cancer therapeutics [9].

adhesion and/or by secreting growth and survival cytokines.

population compared to others [10].

of the hallmarks of cancer [3-5].

Interleukin-6, a pleotropic cytokine, is involved in processes such as haematopoiesis, immunity and inflammation. It was discovered as a factor secreted from mitogen stimulated T cells, which helps mature B cells transform into antibody producing plasma cells [16]. Because of its pleotropic nature, various laboratories were working with its different functions, giving it different names: B cell stimulating factor II (BSF II) as it stimulated B cells to turn into plasma cells and secrete antibodies, interferon-ß2 [17] as it was thought to have the properties of interferon but later it was proven that IL-6 does not have properties of interferon, 26 kDa protein - named after its molecular weight, a hybridoma/plasmacytoma growth factor as it induced plasmacytoma in balb/c mice injected with mineral oil [18] and a hepatocyte-stimulating factor as it stimulated hepatocytes to produce acute phase proteins [19].

IL-6 binds to its receptor, which is either membrane bound or in soluble form. It then activates ubiquitously expressed receptor gp130 [20]. Once gp130 gets activated, IL-6 acts by three of the following signalling pathways: JAK-STAT pathway, MAPK-ERK and PI3-AKT pathway. Most of the actions of IL-6 are executed by JAK-STAT pathway [21]. IL-6 is found to be involved in the growth of many solid tumours like prostate cancer and renal cancer. Pathogenesis of Kaposi sarcoma has been proven to be due to the secretion of IL-6 [22-24]. IL-6 is also involved in the growth of many haematological malignancies.

IL-6 is one of the main growth factors in multiple myeloma [25]. In fact, IL-6 knock out mice failed to develop MM [26]. Moreover, the serum level of IL-6 and soluble IL-6 receptor has

Targeted Inhibition of Multiple Proinflammatory

microenvironment [50, 51].

clinical trials for a variety of cancers.

significant anti-myeloma activity.

**2.3 BAFF and APRIL** 

**2.2 TNFα**

Signalling Pathways for the Prevention and Treatment of Multiple Myeloma 97

Various strategies, including IL-6 antagonist, IL-6 receptor inhibitor (CNTO 328), antisense oligonucleotides against IL-6 and IL-6 super antagonist (SANT7), have been tried for MM, but even after effectively blocking IL-6 receptor by the monoclonal antibody, the results were disappointing in clinical trials [49]. Accordingly, in the presence of bone marrow stromal cells, IL-6 receptor inhibition did not induce apoptosis, indicating the significance of the pleotropism offered by other growth and survival factors present in the bone marrow

In 1894, William Coley noticed that an injection of bacterial extracts into the tumour, could induce necrosis of tumours [52]. O'Malley et al. demonstrated that serum from mice injected with bacterial endotoxin can induce tumour regression [53]. The factor that can induce anticancer activity in vivo and in vitro, present in the sera of mice treated with endotoxin or LPS, was identified as Tumour Necrosis Factor α [54, 55]. The gene expressing human TNFα was cloned in 1984 [56]. Thereafter, the recombinant TNFα was used for experimental and therapeutic purposes. The therapeutic dose of TNFα induced serious hemodynamic instability and septic shock-like symptoms preclinically. TNFα can induce necrosis of the tumour by selective destruction of the blood vessels, only when injected at higher concentrations loco-regionally [57]. Its induction of apoptosis is highly context dependent. Physiologically, TNFα is an important cytokine regulating inflammation, immunity and haematopoiesis. Its deregulation is involved in lots of inflammatory and autoimmune conditions like rheumatoid arthritis and Crohn's disease. Recent research has realised the potent protumerigenic effect of TNFα [58]. TNFα KO and TNFα-R1 KO mice do not develop chemical carcinogen induced skin cancers [59, 60]. TNFα-R1 KO mice do not develop chemical carcinogen induced liver cancer [61]. TNFα antagonists are in various stages of

In MM, TNFα is not a strong growth factor, but it is an important factor secreted from myeloma cells to act on BMSCs to stimulate the secretion of IL-6. TNFα induces the expression of adhesion molecules on both myeloma cells and BMSCs. TNFα secreted by myeloma cells acts both directly and by increasing the adhesion between myeloma cells and the bone marrow stromal cells to secrete IL-6 by an NF-κB mediated mechanism in bone marrow stromal cells. TNFα is very potent when compared to other growth factors [62]. TNFα also participates in transendothelial migration of myeloma cells by acting via TNF-R2 and upregulating the secretion of MCP-1 in myeloma cells [63]. Clinically, the agents which are known to inhibit TNFα; namely, thalidomide and its derivates and bortezomib, have

BAFF and APRIL also belong to the TNF family of cytokines. They act by binding to receptors TACI (transmembrane activator and calcium modulator, and cyclophilin ligand interactor), BCMA (B-cell maturation antigen) and BAFF-R (BAFF Receptor) which is specific for BAFF. Myeloma cells express these receptors in a heterogeneous manner [64]. In fact, patient groups whose myeloma cells had low expression of TACI receptor were less differentiated and showed attenuated dependence on the bone marrow and portending

been proven to be a prognostic marker for tumour load, disease progression and survival [27-31]. Moreover, serum levels of IL-6 in patients with smouldering MM and monoclonal gammapathy of undetermined significance are comparable with healthy individuals, indicating the important role of IL-6 in the disease progression [32].

Initially, it was thought based on the following findings that myeloma cells secrete and respond to IL-6 in an autocrine manner. Firstly, IL-6 induces in vitro growth of freshly isolated MM cells. Secondly, MM cells express the IL-6 receptor (IL-6R). Thirdly, purified MM cells produce IL-6 and lastly, in vitro growth of MM cells is inhibited by anti-IL-6 antibodies [33]. But, again controversies prevailed among the research laboratories on the autocrine secretion of IL-6 by myeloma cells. Because, though all myeloma derived cell lines and patients cells express IL-6 receptor, only subsets of cell lines express IL-6 mRNA [34]. It was also found that bone marrow stromal cells are the main source of IL-6 [35-37]. Interestingly, when myeloma cells were co-cultured with bone marrow stromal cells, they tend to adhere to each other tightly and the IL-6 secretion by these cells reaches the peak. But, when the bone marrow stromal cells were fixed by paraformaldehyde, there was no increase in the level of IL- 6, confirming that the source of IL-6 was bone marrow stromal cells and not myeloma cells. Moreover, it was found that the stromal cells secrete IL-6 when stimulated by the adhesion of myeloma cells to the stromal cells. This is evident from experimental setup where these cells were cultured in transwell chambers without any physical contact with the myeloma cells. As a result, the bone marrow cells failed to secrete IL-6, emphasising the importance of adhesion molecules in the cross talk between the group of cells and pathophysiology of myeloma [38]. The adhesion mediated secretion of IL-6 was found to be NF-κB dependent [39].

In addition to bone marrow stromal cells, adhesion of myeloma cells to the peripheral blood derived osteoclastic cells protected myeloma cells from serum deprivation induced apoptosis and doxorubicin induced apoptosis. Osteoclasts produced osteopontin (OPN) and IL-6, and adhesion of MM cells to osteocleasts increased IL-6 production from osteoclasts. In addition, IL-6 and osteopontin in combination, enhanced MM cell growth and survival. However, the effects of osteoclasts on MM cell growth and survival were only partially suppressed by a simultaneous addition of anti–IL-6 and anti-osteopontin antibodies and were completely abrogated by inhibition of cellular contact between MM cells and osteoclasts. Osteoclasts enhance MM cell growth and survival through a cell-cell contactmediated mechanism that is partially dependent on IL-6 and osteopontin [40].

The IL-6 induced survival of myeloma cells is mediated by STAT3, which upregulates antiapoptotic proteins Bcl-XL and Mcl-1 and cell cycle proteins like cyclin D1, c-Myc and Pim. The IL-6 induced proliferation is mediated by MAPK-ERK pathway [41]. A PI3-AKT pathway mediates proliferation and induces survival by phosphorilating Bad and activating cell cycle proteins and NF-κB. Gene expression profiling studies demonstrated that out of 138 genes shown to be regulated by IL-6 in myeloma cells, 54% regulated cell cycle progression. This finding emphasises the role of IL-6 in myeloma cell proliferation [42]. IL-6 was shown to inhibit Fos induced apoptosis [43]. IL-6 can inhibit dexamethasone induced apoptosis of myeloma cells by gp130 induced activation of SHP2, which deactivates related adhesion focal tyrosine kinase (RAFTK) [44, 45] and activates the PI3/AKT pathway [46]. Partial reduction in the levels of IL-6 can sensitise the myeloma cells to chemotherapeutic agents [47, 48].

Various strategies, including IL-6 antagonist, IL-6 receptor inhibitor (CNTO 328), antisense oligonucleotides against IL-6 and IL-6 super antagonist (SANT7), have been tried for MM, but even after effectively blocking IL-6 receptor by the monoclonal antibody, the results were disappointing in clinical trials [49]. Accordingly, in the presence of bone marrow stromal cells, IL-6 receptor inhibition did not induce apoptosis, indicating the significance of the pleotropism offered by other growth and survival factors present in the bone marrow microenvironment [50, 51].

#### **2.2 TNFα**

96 Multiple Myeloma – An Overview

been proven to be a prognostic marker for tumour load, disease progression and survival [27-31]. Moreover, serum levels of IL-6 in patients with smouldering MM and monoclonal gammapathy of undetermined significance are comparable with healthy individuals,

Initially, it was thought based on the following findings that myeloma cells secrete and respond to IL-6 in an autocrine manner. Firstly, IL-6 induces in vitro growth of freshly isolated MM cells. Secondly, MM cells express the IL-6 receptor (IL-6R). Thirdly, purified MM cells produce IL-6 and lastly, in vitro growth of MM cells is inhibited by anti-IL-6 antibodies [33]. But, again controversies prevailed among the research laboratories on the autocrine secretion of IL-6 by myeloma cells. Because, though all myeloma derived cell lines and patients cells express IL-6 receptor, only subsets of cell lines express IL-6 mRNA [34]. It was also found that bone marrow stromal cells are the main source of IL-6 [35-37]. Interestingly, when myeloma cells were co-cultured with bone marrow stromal cells, they tend to adhere to each other tightly and the IL-6 secretion by these cells reaches the peak. But, when the bone marrow stromal cells were fixed by paraformaldehyde, there was no increase in the level of IL- 6, confirming that the source of IL-6 was bone marrow stromal cells and not myeloma cells. Moreover, it was found that the stromal cells secrete IL-6 when stimulated by the adhesion of myeloma cells to the stromal cells. This is evident from experimental setup where these cells were cultured in transwell chambers without any physical contact with the myeloma cells. As a result, the bone marrow cells failed to secrete IL-6, emphasising the importance of adhesion molecules in the cross talk between the group of cells and pathophysiology of myeloma [38]. The adhesion mediated secretion of IL-6 was

In addition to bone marrow stromal cells, adhesion of myeloma cells to the peripheral blood derived osteoclastic cells protected myeloma cells from serum deprivation induced apoptosis and doxorubicin induced apoptosis. Osteoclasts produced osteopontin (OPN) and IL-6, and adhesion of MM cells to osteocleasts increased IL-6 production from osteoclasts. In addition, IL-6 and osteopontin in combination, enhanced MM cell growth and survival. However, the effects of osteoclasts on MM cell growth and survival were only partially suppressed by a simultaneous addition of anti–IL-6 and anti-osteopontin antibodies and were completely abrogated by inhibition of cellular contact between MM cells and osteoclasts. Osteoclasts enhance MM cell growth and survival through a cell-cell contact-

The IL-6 induced survival of myeloma cells is mediated by STAT3, which upregulates antiapoptotic proteins Bcl-XL and Mcl-1 and cell cycle proteins like cyclin D1, c-Myc and Pim. The IL-6 induced proliferation is mediated by MAPK-ERK pathway [41]. A PI3-AKT pathway mediates proliferation and induces survival by phosphorilating Bad and activating cell cycle proteins and NF-κB. Gene expression profiling studies demonstrated that out of 138 genes shown to be regulated by IL-6 in myeloma cells, 54% regulated cell cycle progression. This finding emphasises the role of IL-6 in myeloma cell proliferation [42]. IL-6 was shown to inhibit Fos induced apoptosis [43]. IL-6 can inhibit dexamethasone induced apoptosis of myeloma cells by gp130 induced activation of SHP2, which deactivates related adhesion focal tyrosine kinase (RAFTK) [44, 45] and activates the PI3/AKT pathway [46]. Partial reduction in the levels of IL-6 can sensitise the myeloma cells to chemotherapeutic

mediated mechanism that is partially dependent on IL-6 and osteopontin [40].

indicating the important role of IL-6 in the disease progression [32].

found to be NF-κB dependent [39].

agents [47, 48].

In 1894, William Coley noticed that an injection of bacterial extracts into the tumour, could induce necrosis of tumours [52]. O'Malley et al. demonstrated that serum from mice injected with bacterial endotoxin can induce tumour regression [53]. The factor that can induce anticancer activity in vivo and in vitro, present in the sera of mice treated with endotoxin or LPS, was identified as Tumour Necrosis Factor α [54, 55]. The gene expressing human TNFα was cloned in 1984 [56]. Thereafter, the recombinant TNFα was used for experimental and therapeutic purposes. The therapeutic dose of TNFα induced serious hemodynamic instability and septic shock-like symptoms preclinically. TNFα can induce necrosis of the tumour by selective destruction of the blood vessels, only when injected at higher concentrations loco-regionally [57]. Its induction of apoptosis is highly context dependent. Physiologically, TNFα is an important cytokine regulating inflammation, immunity and haematopoiesis. Its deregulation is involved in lots of inflammatory and autoimmune conditions like rheumatoid arthritis and Crohn's disease. Recent research has realised the potent protumerigenic effect of TNFα [58]. TNFα KO and TNFα-R1 KO mice do not develop chemical carcinogen induced skin cancers [59, 60]. TNFα-R1 KO mice do not develop chemical carcinogen induced liver cancer [61]. TNFα antagonists are in various stages of clinical trials for a variety of cancers.

In MM, TNFα is not a strong growth factor, but it is an important factor secreted from myeloma cells to act on BMSCs to stimulate the secretion of IL-6. TNFα induces the expression of adhesion molecules on both myeloma cells and BMSCs. TNFα secreted by myeloma cells acts both directly and by increasing the adhesion between myeloma cells and the bone marrow stromal cells to secrete IL-6 by an NF-κB mediated mechanism in bone marrow stromal cells. TNFα is very potent when compared to other growth factors [62]. TNFα also participates in transendothelial migration of myeloma cells by acting via TNF-R2 and upregulating the secretion of MCP-1 in myeloma cells [63]. Clinically, the agents which are known to inhibit TNFα; namely, thalidomide and its derivates and bortezomib, have significant anti-myeloma activity.

#### **2.3 BAFF and APRIL**

BAFF and APRIL also belong to the TNF family of cytokines. They act by binding to receptors TACI (transmembrane activator and calcium modulator, and cyclophilin ligand interactor), BCMA (B-cell maturation antigen) and BAFF-R (BAFF Receptor) which is specific for BAFF. Myeloma cells express these receptors in a heterogeneous manner [64]. In fact, patient groups whose myeloma cells had low expression of TACI receptor were less differentiated and showed attenuated dependence on the bone marrow and portending

Targeted Inhibition of Multiple Proinflammatory

**2.5 Fibroblast Growth Factor (FGF)** 

with respect to the above cytokines [97].

to downstream targets at the cell membrane.

**2.6 Transforming Growth Factor (TGF-β)** 

inhibitors in cancer.

Signalling Pathways for the Prevention and Treatment of Multiple Myeloma 99

Therapies targeting IGF-1, such as inhibitors of IGF-1 receptor, have already shown preclinical anti-MM activity and will soon undergo clinical evaluation [75]. IGF-1R inhibition with neutralizing antibody, antagonistic peptide, or the selective kinase inhibitor NVP-ADW742 has in vitro activity against MM cell types and in orthotopic xenograft MM model had synergistic anti-tumour activity in combination with conventional chemotherapy. Another study [90] reports that IGF-1R inhibition blunts tumour cell response to other growth factors, overcomes the drug resistance phenotype conferred by the bone microenvironment and abrogates the production of proangiogenic cytokines. These sets of studies provide in vivo proof of the principle for therapeutic use of selective IGF-1R

Besides bone marrow microvessel density (MVD), serum levels of FGF, along with VEGF, are predicted to be prognostic markers of MM disease activity [91, 92]. Expression of bFGF correlates with clinical characteristics of MM and its high level also indicates poor prognosis [93]. However, the levels of bFGF may serve as a predictor for good response to the treatment of MM with Thalidomide [94]. Patients responsive to Thalidomide may have significantly higher concentrations of bFGF than non-responsive patients, but this observation is not consistent even between the same authors [95, 96]. Stimulation of BMSCs with FGF-2 induced a time and dose-dependent increase in IL-6 secretion, a well studied cytokine, which was completely abrogated by anti-bFGF antibodies. Conversely, stimulation with IL-6 enhanced bFGF expression and secretion by myeloma cell lines as well as MM patient cells, suggested a paracrine interaction between the myeloma and the stromal cells

The FGF receptor 3 (FGFR3) is now recognized as a potential oncogene. Ectopic expression of FGFR3 originates from the translocation t(4;14) occurring in 10-25% of MM patients [98, 99]. Gain of function mutations in FGF receptors, especially FGFR3, have been widely implicated and studied in MM pathogenesis [98]. Suppression of FGFR3 using short hairpin

FGF binding to the FGFR, results in dimerization of the receptor and autophosphorylation of the FGFR dimer at intracellular tyrosine residues. The activated receptor either binds directly to signalling molecules or recruits adapter molecules to link the activated receptor

Three FGF signalling downstream pathways have been identified in MM [102]: the Ras mitogen-activated protein kinase (MAPK) pathway, the phosphoinositol pathway and the

Transforming Growth Factor beta (TGF-β) is a growth factor that controls proliferation, cellular growth and differentiation [103], and embryonic development [104]. During tumourigenesis, the TGF-β signalling pathway becomes mutated and TGF-β no longer controls the cell cycle [105, 106]. The cancer cells along with the surrounding stromal cells (fibroblasts) proliferate unchecked. Both these cells increase their production of TGF-β,

RNAs (shRNAs), lead to apoptosis and anti-tumour effects in MM [100, 101].

signal transducer and activator of transcription (STAT) pathway.

poor prognosis; whereas patients whose myeloma cells express high levels of TACI receptor showed mature plasma cell signature exhibiting good prognosis [65]. There is evidence for these cytokines being secreted from myeloma cells [64, 66], bone marrow cells [67] and osteoclastic cells [65]. BAFF and APRIL seem to induce myeloma cell growth and inhibit dexamethasone induced apoptosis. BAFF and APRIL activate NF-κB, PI3kinase/AKT, and MAPK pathways in myeloma cells and induce a strong upregulation of the Mcl-1 and Bcl-2 anti-apoptotic proteins [68, 69]. Cell adhesion induced bone marrow cells secrete BAFF, which acts on myeloma cells to regulate their growth and survival [67]. Interestingly, bortezomib has been found to inhibit BAFF and APRIL induce proliferation of myeloma cells [66].

#### **2.4 Insulin-like Growth Factor 1 (IGF-1)**

Recent studies have delineated the role of IGF-1 in MM. IGF-1 was shown to be a strong indicator of prognosis in MM patients [70]. In the bone marrow milieu, IGF-1 is mainly produced and secreted from bone marrow stromal cells and mediates cell growth and survival in MM cells both in vitro [71, 72] and in vivo [73-75]. IGF-1 and its receptor were shown to be acting as growth factors [76] and preferentially expressed in MM cells [77] as compared to B-Lymphoblastoid cell lines.

IGF-1 inhibits Dexametasone-induced apoptosis in MM cell lines [78]. IGF-1 augments the proliferative and anti-apoptotic effects of IL-6 [71, 79] . Although IL-6 has mostly been described as a proliferation factor for MM, it has become clear that IGF-1 has an equally important proliferative and anti-apoptotic effect [80-82]. It could be that IGF-1 plays an even more pivotal role in the survival of MM cells, as IL-6 independent lines still respond to IGF-1 [80, 82]. Another group demonstrates that IGF-1 serves as a chemoattractant for MM cells [73]. In vivo induction of the receptor IGF-1R helps murine multiple myeloma cells in their homing and growth in the bone marrow [83].

IGF-1 transduces its signal by receptor phosphorylation of the insulin response substrate 1 and its activation of PI-3K and subsequently Akt kinase (PI-3K pathway). In fact, IGF-I increases adhesion of MM cell lines to fibronectin (FN) in a time and dose-dependent manner, as a consequence of IGF-1R activation and subsequent activation of β1- integrin and PI3-kinase/AKT signalling [84]. Several important biological characteristics have been associated with this segment of the PI-3K pathway [85]. Akt subsequently phosphorylates Bad, a member of the Bcl-2 family, producing an anti-apoptotic effect. The second pathway associated with IGF-I stimulation signals through the Shc, Grb-2, Sos complex, resulting in activation of Ras and subsequently the mitogen-activated protein kinase (MAPK) signalling cascade.

IGF-1 is also shown to mediate the activation of NF-κB [86], induce the phosphorylation of FKHR (forkhead) transcription factor, upregulate a series of intracellular anti-apoptotic proteins (including FLIP, survivin, cIAP-2, A1/Bfl-1 and XIAP) and decrease drug sensitivity of MM cells [75]. Caveolin-1, which is usually absent in blood cells, is expressed in MM cells and plays a crucial role in IGF-1-mediated signalling cascades [87]. Specifically, IGF-1 induces HIF-1α, which triggers VEGF expression [88, 89]; consequently, inhibition of IGFR-1 activity markedly decreases VEGF secretion in MM/BMSC co-cultures [75].

Therapies targeting IGF-1, such as inhibitors of IGF-1 receptor, have already shown preclinical anti-MM activity and will soon undergo clinical evaluation [75]. IGF-1R inhibition with neutralizing antibody, antagonistic peptide, or the selective kinase inhibitor NVP-ADW742 has in vitro activity against MM cell types and in orthotopic xenograft MM model had synergistic anti-tumour activity in combination with conventional chemotherapy. Another study [90] reports that IGF-1R inhibition blunts tumour cell response to other growth factors, overcomes the drug resistance phenotype conferred by the bone microenvironment and abrogates the production of proangiogenic cytokines. These sets of studies provide in vivo proof of the principle for therapeutic use of selective IGF-1R inhibitors in cancer.

#### **2.5 Fibroblast Growth Factor (FGF)**

98 Multiple Myeloma – An Overview

poor prognosis; whereas patients whose myeloma cells express high levels of TACI receptor showed mature plasma cell signature exhibiting good prognosis [65]. There is evidence for these cytokines being secreted from myeloma cells [64, 66], bone marrow cells [67] and osteoclastic cells [65]. BAFF and APRIL seem to induce myeloma cell growth and inhibit dexamethasone induced apoptosis. BAFF and APRIL activate NF-κB, PI3kinase/AKT, and MAPK pathways in myeloma cells and induce a strong upregulation of the Mcl-1 and Bcl-2 anti-apoptotic proteins [68, 69]. Cell adhesion induced bone marrow cells secrete BAFF, which acts on myeloma cells to regulate their growth and survival [67]. Interestingly, bortezomib has been found to inhibit BAFF and APRIL induce proliferation of myeloma

Recent studies have delineated the role of IGF-1 in MM. IGF-1 was shown to be a strong indicator of prognosis in MM patients [70]. In the bone marrow milieu, IGF-1 is mainly produced and secreted from bone marrow stromal cells and mediates cell growth and survival in MM cells both in vitro [71, 72] and in vivo [73-75]. IGF-1 and its receptor were shown to be acting as growth factors [76] and preferentially expressed in MM cells [77] as

IGF-1 inhibits Dexametasone-induced apoptosis in MM cell lines [78]. IGF-1 augments the proliferative and anti-apoptotic effects of IL-6 [71, 79] . Although IL-6 has mostly been described as a proliferation factor for MM, it has become clear that IGF-1 has an equally important proliferative and anti-apoptotic effect [80-82]. It could be that IGF-1 plays an even more pivotal role in the survival of MM cells, as IL-6 independent lines still respond to IGF-1 [80, 82]. Another group demonstrates that IGF-1 serves as a chemoattractant for MM cells [73]. In vivo induction of the receptor IGF-1R helps murine multiple myeloma cells in their

IGF-1 transduces its signal by receptor phosphorylation of the insulin response substrate 1 and its activation of PI-3K and subsequently Akt kinase (PI-3K pathway). In fact, IGF-I increases adhesion of MM cell lines to fibronectin (FN) in a time and dose-dependent manner, as a consequence of IGF-1R activation and subsequent activation of β1- integrin and PI3-kinase/AKT signalling [84]. Several important biological characteristics have been associated with this segment of the PI-3K pathway [85]. Akt subsequently phosphorylates Bad, a member of the Bcl-2 family, producing an anti-apoptotic effect. The second pathway associated with IGF-I stimulation signals through the Shc, Grb-2, Sos complex, resulting in activation of Ras and subsequently the mitogen-activated protein

IGF-1 is also shown to mediate the activation of NF-κB [86], induce the phosphorylation of FKHR (forkhead) transcription factor, upregulate a series of intracellular anti-apoptotic proteins (including FLIP, survivin, cIAP-2, A1/Bfl-1 and XIAP) and decrease drug sensitivity of MM cells [75]. Caveolin-1, which is usually absent in blood cells, is expressed in MM cells and plays a crucial role in IGF-1-mediated signalling cascades [87]. Specifically, IGF-1 induces HIF-1α, which triggers VEGF expression [88, 89]; consequently, inhibition of

IGFR-1 activity markedly decreases VEGF secretion in MM/BMSC co-cultures [75].

cells [66].

**2.4 Insulin-like Growth Factor 1 (IGF-1)** 

compared to B-Lymphoblastoid cell lines.

homing and growth in the bone marrow [83].

kinase (MAPK) signalling cascade.

Besides bone marrow microvessel density (MVD), serum levels of FGF, along with VEGF, are predicted to be prognostic markers of MM disease activity [91, 92]. Expression of bFGF correlates with clinical characteristics of MM and its high level also indicates poor prognosis [93]. However, the levels of bFGF may serve as a predictor for good response to the treatment of MM with Thalidomide [94]. Patients responsive to Thalidomide may have significantly higher concentrations of bFGF than non-responsive patients, but this observation is not consistent even between the same authors [95, 96]. Stimulation of BMSCs with FGF-2 induced a time and dose-dependent increase in IL-6 secretion, a well studied cytokine, which was completely abrogated by anti-bFGF antibodies. Conversely, stimulation with IL-6 enhanced bFGF expression and secretion by myeloma cell lines as well as MM patient cells, suggested a paracrine interaction between the myeloma and the stromal cells with respect to the above cytokines [97].

The FGF receptor 3 (FGFR3) is now recognized as a potential oncogene. Ectopic expression of FGFR3 originates from the translocation t(4;14) occurring in 10-25% of MM patients [98, 99]. Gain of function mutations in FGF receptors, especially FGFR3, have been widely implicated and studied in MM pathogenesis [98]. Suppression of FGFR3 using short hairpin RNAs (shRNAs), lead to apoptosis and anti-tumour effects in MM [100, 101].

FGF binding to the FGFR, results in dimerization of the receptor and autophosphorylation of the FGFR dimer at intracellular tyrosine residues. The activated receptor either binds directly to signalling molecules or recruits adapter molecules to link the activated receptor to downstream targets at the cell membrane.

Three FGF signalling downstream pathways have been identified in MM [102]: the Ras mitogen-activated protein kinase (MAPK) pathway, the phosphoinositol pathway and the signal transducer and activator of transcription (STAT) pathway.

#### **2.6 Transforming Growth Factor (TGF-β)**

Transforming Growth Factor beta (TGF-β) is a growth factor that controls proliferation, cellular growth and differentiation [103], and embryonic development [104]. During tumourigenesis, the TGF-β signalling pathway becomes mutated and TGF-β no longer controls the cell cycle [105, 106]. The cancer cells along with the surrounding stromal cells (fibroblasts) proliferate unchecked. Both these cells increase their production of TGF-β,

Targeted Inhibition of Multiple Proinflammatory

**3.2 MCP1 (or monocyte chemoattractant protein - CCL2)** 

together, suggesting the role of various MCPs in myeloma homing [121].

**3.3 CXC chemokines and CXCR3 receptor involvement in MM** 

**3.4 Stromal Derived Factor (SDF-1α/CXCL12)** 

homing to about 40% [125].

Signalling Pathways for the Prevention and Treatment of Multiple Myeloma 101

As mentioned earlier, endothelial cells play an active role in the extravasation of myeloma cells and eventually their homing to the microenvironment. Murine endothelial cells are shown to secrete CCL2 and murine myeloma cells express the cognate receptor CCR2. Myeloma cells migrated towards the endothelial cell conditioned medium and this migration was inhibited by using antibodies against MCP1 [120]. Human bone marrow stromal cells also secrete MCP1, MCP2 and MCP 3, and myeloma cells migrate towards a stromal cell conditioned medium. This effect was inhibited by using antibodies against the MCPs and maximal inhibition was observed when all the three MCPs were blocked

CXCR3 receptor is expressed by activated T cells. It binds to CXC chemokines namely,: CXCL11 or Interferon-inducible T-cell Alpha Chemoattractant (I-TAC), Mig (Monocyte/macrophage-activating IFNϒ-inducible protein)/CXCL9 and IP10 (IFNϒ inducible 10 kDa protein)/CXCL10. Myeloma cells derived from patients with myeloma, as well as myeloma derived cell lines, express CXCR3 receptor and they respond to their ligands by inducing tyrosine kinase phosphorylation and secreting MMP2 and MMP9 [122]. Bone marrow endothelial cells also secrete CXC chemokines and certain myeloma cells

Stromal derived factor is a member of CXC family of cytokines and its cognate receptor is CXCR4. CXC12/CXCR4 is the most extensively studied chemokine/receptor system with respect to cancer. It has been implicated in progression, migration, invasion and metastasis of various cancers. The role of CXC12/CXCR4 has been well established in the homing of haematopoietic progenitor cells. Bone marrow plasma and bone marrow stromal cells secrete this chemokine, with the myeloma cells from the patient sample and myeloma derived cell lines expressing the cognate receptors. The chemokine mediates the secretion of IL-6 and VEGF, and induces proliferation, migration and inhibits dexamethasone induced cell death [124]. In the 5TMM model, bone marrow stromal cells and endothelial cells secrete SDF-1α and myeloma cells express the receptor. In vitro, SDF-1α induces moderate proliferation of myeloma cells, which was abrogated by blocking antibodies. 5T myeloma cells migrated towards a stromal cells conditioned medium which was partially inhibited by CXCR4 inhibitor. SDF also stimulated myeloma cells to secrete MMP9, demonstrated by zymography. Accordingly, SDF induces invasion and the CXCR4 inhibitor inhibits SDF induced invasion. In vivo, CXCR4 inhibitor inhibited the tumour burden and the immediate

When the myeloma cells were mobilized, the CXCL12/CXCR4 axis is downregulated. There is a downregulation of very late antigen (VLA4) in the peripheral blood myeloma cells after mobilization. This results in a suppression of the adhesion of myeloma cells to the bone marrow stromal cells, which can be rescued by induction with IL-6 [126]. Moreover, bone marrow endothelial cells are also shown to secrete CXCL12 and induce migration of myeloma cells towards the bone marrow endothelial cells. Thus, angiogenesis induced

expressing their cognate receptors migrate in response to these chemokines [123].

which acts on the surrounding stromal cells, immune cells, endothelial and smooth-muscle cells, causing immunosuppression [106, 107] and tumour angiogenesis, and increasing the invasiveness [108, 109] and motility [110] of cancer.

TGF-β also plays a role in the suppression of bone formation in MM bone lesions [111]. Overproduction of TGF-beta 1 in MM patients was reported by Kroning et al. [112]. TGF-β is mainly produced by BMSCs, but is also secreted by malignant plasma cells and can regulate interleukin-6 (IL-6) secretion [113]. According to Cook et al., TGF-β produced by MM cells plays a significant role in suppressing host T cells and immune responses [114, 115]. TGF-β inhibition was able to suppress MM cell growth within the bone marrow while preventing bone destruction in MM-bearing animal models [116].

#### **3. Role of chemokines**

In MM, chemokines mainly help homing the myeloma cells to the bone marrow microenvironment. Their role in proliferation and survival of myeloma cells is only moderate. This effect can be either direct or mediated indirectly by inducing the secretion of IL-6, VEGF, or any other growth factor involved in the growth and survival of myeloma cells. The role of chemokines, especially that of MIPs, in osteolytic bone lesions is well established. Homing is defined by transendothelial migration of cells from the blood stream towards the chemokine gradient. This involves adhesion of cells to the endothelial layer, transendothelial migration and eventually residing in the microenvironment. So, it is apparent that bone marrow endothelial cells play an active role in the migration of plasma cells. They do so by secreting various chemokines and expressing adhesion molecules; thereby helping myeloma cells to migrate towards them. Upon adherence, MM cells will extravasate using their MMP arsenal to move through the basal lamina of bone marrow sinusoids. This process is also aided by the chemokine gradient in the bone marrow microenvironment because certain chemokine are said to be present in higher concentrations in the bone marrow microenvironment than in bone marrow endothelial cells which make sure that the cells are confined to the bone marrow microenvironment.

#### **3.1 Macrophage Inflammatory protein: (MIP-1, CCL3)**

MIP1 belongs to the CC family of chemokine and mainly acts via CCR1, CCR5 and CCR9 receptors. Myeloma cells have been shown to express both the receptors (CCR1, CCR5) and the chemokine [117, 118]. Controversial findings on the effect of growth and survival of myeloma cells could be due to usage of different experimental models and design [118, 119], but its role in migration and homing of myeloma cells, and in the progression of the myeloma bone disease, are clearly demonstrated. SCID mice injected with stable MIP1 knock-down clones of ARH cell line showed comparably less adhesion to the bone marrow, reduced survival and less bone pathology when compared to wild type ARH cell line injected group [117]. Suzanne Lentzsch et al. showed in vitro evidence that MIP1α can induce myeloma cell migration. Interestingly, they also showed that MIP1α can induce proliferation and survival of myeloma cells by inducing MAPK/ERK pathway, PI3/AKT pathway [118]. There is a study in which the various effects of MIP1α on 5TMM has been dissected. MIP1α induced migration has been attributed to the CCR5 and CCR1 receptor mediated signalling. Both the receptors mediate the MIP1α induced bone marrow angiogenesis and at least CCR1 mediates this effect directly [119].

#### **3.2 MCP1 (or monocyte chemoattractant protein - CCL2)**

100 Multiple Myeloma – An Overview

which acts on the surrounding stromal cells, immune cells, endothelial and smooth-muscle cells, causing immunosuppression [106, 107] and tumour angiogenesis, and increasing the

TGF-β also plays a role in the suppression of bone formation in MM bone lesions [111]. Overproduction of TGF-beta 1 in MM patients was reported by Kroning et al. [112]. TGF-β is mainly produced by BMSCs, but is also secreted by malignant plasma cells and can regulate interleukin-6 (IL-6) secretion [113]. According to Cook et al., TGF-β produced by MM cells plays a significant role in suppressing host T cells and immune responses [114, 115]. TGF-β inhibition was able to suppress MM cell growth within the bone marrow while preventing

In MM, chemokines mainly help homing the myeloma cells to the bone marrow microenvironment. Their role in proliferation and survival of myeloma cells is only moderate. This effect can be either direct or mediated indirectly by inducing the secretion of IL-6, VEGF, or any other growth factor involved in the growth and survival of myeloma cells. The role of chemokines, especially that of MIPs, in osteolytic bone lesions is well established. Homing is defined by transendothelial migration of cells from the blood stream towards the chemokine gradient. This involves adhesion of cells to the endothelial layer, transendothelial migration and eventually residing in the microenvironment. So, it is apparent that bone marrow endothelial cells play an active role in the migration of plasma cells. They do so by secreting various chemokines and expressing adhesion molecules; thereby helping myeloma cells to migrate towards them. Upon adherence, MM cells will extravasate using their MMP arsenal to move through the basal lamina of bone marrow sinusoids. This process is also aided by the chemokine gradient in the bone marrow microenvironment because certain chemokine are said to be present in higher concentrations in the bone marrow microenvironment than in bone marrow endothelial cells

which make sure that the cells are confined to the bone marrow microenvironment.

MIP1 belongs to the CC family of chemokine and mainly acts via CCR1, CCR5 and CCR9 receptors. Myeloma cells have been shown to express both the receptors (CCR1, CCR5) and the chemokine [117, 118]. Controversial findings on the effect of growth and survival of myeloma cells could be due to usage of different experimental models and design [118, 119], but its role in migration and homing of myeloma cells, and in the progression of the myeloma bone disease, are clearly demonstrated. SCID mice injected with stable MIP1 knock-down clones of ARH cell line showed comparably less adhesion to the bone marrow, reduced survival and less bone pathology when compared to wild type ARH cell line injected group [117]. Suzanne Lentzsch et al. showed in vitro evidence that MIP1α can induce myeloma cell migration. Interestingly, they also showed that MIP1α can induce proliferation and survival of myeloma cells by inducing MAPK/ERK pathway, PI3/AKT pathway [118]. There is a study in which the various effects of MIP1α on 5TMM has been dissected. MIP1α induced migration has been attributed to the CCR5 and CCR1 receptor mediated signalling. Both the receptors mediate the MIP1α induced bone marrow

invasiveness [108, 109] and motility [110] of cancer.

bone destruction in MM-bearing animal models [116].

**3.1 Macrophage Inflammatory protein: (MIP-1, CCL3)** 

angiogenesis and at least CCR1 mediates this effect directly [119].

**3. Role of chemokines** 

As mentioned earlier, endothelial cells play an active role in the extravasation of myeloma cells and eventually their homing to the microenvironment. Murine endothelial cells are shown to secrete CCL2 and murine myeloma cells express the cognate receptor CCR2. Myeloma cells migrated towards the endothelial cell conditioned medium and this migration was inhibited by using antibodies against MCP1 [120]. Human bone marrow stromal cells also secrete MCP1, MCP2 and MCP 3, and myeloma cells migrate towards a stromal cell conditioned medium. This effect was inhibited by using antibodies against the MCPs and maximal inhibition was observed when all the three MCPs were blocked together, suggesting the role of various MCPs in myeloma homing [121].

#### **3.3 CXC chemokines and CXCR3 receptor involvement in MM**

CXCR3 receptor is expressed by activated T cells. It binds to CXC chemokines namely,: CXCL11 or Interferon-inducible T-cell Alpha Chemoattractant (I-TAC), Mig (Monocyte/macrophage-activating IFNϒ-inducible protein)/CXCL9 and IP10 (IFNϒ inducible 10 kDa protein)/CXCL10. Myeloma cells derived from patients with myeloma, as well as myeloma derived cell lines, express CXCR3 receptor and they respond to their ligands by inducing tyrosine kinase phosphorylation and secreting MMP2 and MMP9 [122]. Bone marrow endothelial cells also secrete CXC chemokines and certain myeloma cells expressing their cognate receptors migrate in response to these chemokines [123].

#### **3.4 Stromal Derived Factor (SDF-1α/CXCL12)**

Stromal derived factor is a member of CXC family of cytokines and its cognate receptor is CXCR4. CXC12/CXCR4 is the most extensively studied chemokine/receptor system with respect to cancer. It has been implicated in progression, migration, invasion and metastasis of various cancers. The role of CXC12/CXCR4 has been well established in the homing of haematopoietic progenitor cells. Bone marrow plasma and bone marrow stromal cells secrete this chemokine, with the myeloma cells from the patient sample and myeloma derived cell lines expressing the cognate receptors. The chemokine mediates the secretion of IL-6 and VEGF, and induces proliferation, migration and inhibits dexamethasone induced cell death [124]. In the 5TMM model, bone marrow stromal cells and endothelial cells secrete SDF-1α and myeloma cells express the receptor. In vitro, SDF-1α induces moderate proliferation of myeloma cells, which was abrogated by blocking antibodies. 5T myeloma cells migrated towards a stromal cells conditioned medium which was partially inhibited by CXCR4 inhibitor. SDF also stimulated myeloma cells to secrete MMP9, demonstrated by zymography. Accordingly, SDF induces invasion and the CXCR4 inhibitor inhibits SDF induced invasion. In vivo, CXCR4 inhibitor inhibited the tumour burden and the immediate homing to about 40% [125].

When the myeloma cells were mobilized, the CXCL12/CXCR4 axis is downregulated. There is a downregulation of very late antigen (VLA4) in the peripheral blood myeloma cells after mobilization. This results in a suppression of the adhesion of myeloma cells to the bone marrow stromal cells, which can be rescued by induction with IL-6 [126]. Moreover, bone marrow endothelial cells are also shown to secrete CXCL12 and induce migration of myeloma cells towards the bone marrow endothelial cells. Thus, angiogenesis induced

Targeted Inhibition of Multiple Proinflammatory

**4.2 NF-κB pathway** 

pathway.

chain joining (J) segment gene region in B cells [178].

Signalling Pathways for the Prevention and Treatment of Multiple Myeloma 103

34 (79.4%) myeloma samples showed SHP1 hypermethylation. At least in U266 MM cells, methylation of SHP1 may be responsible for constitutive STAT3 activation, because treatment with 5-azacytidine, a DNA demethylator, led to a progressive demethylation of SHP1 and a parallel downregulation of phosphorylated STAT3 [15]. SOCS-1 is hypermethylated in 23 out of 35 (62.9%) MM patient samples and consistently expression of this protein is upregulated after treatment with demethylators. So, it can be concluded that suppression of the expression of negative regulators of IL6-JAK-S TAT pathway by epigenetic silencing increases the sensitivity of myeloma cells to IL-6 induced proliferation and survival [141]. Moreover, overexpression of SOCS using adenoviral vector inhibited the IL-6 induced proliferation in IL-6 dependent multiple myeloma cells, hinting at another

There are lots of therapeutic strategies that are being developed to target JAK-STAT3 pathway in MM. In fact, the novel agents that are being used nowadays namely, thalidomide and its derivatives and bortezomib, act partially to disrupt the NF-κB induced activation of IL-6 and thereby STAT3 activation. Numerous drugs that inhibit IL-6-JAK-STAT3 pathway at various levels induce apoptosis, both in vitro and in vivo [143-175].

NF-κB is a Rel family of transcription factors consisting of p50, p52, c-Rel, p65/RelA and RelB subunits [176, 177]. It was discovered by Dr. Baltimore and colleagues in 1986 as a DNA binding protein, recognising specific sequences in the immunoglobulin kappa light

Various inflammatory stimuli activate the NF-κB pathway. There are two pathways involved in the activation of the NF-κB pathway: the classical pathway and the alternative

NF-κB is a main transcription factor regulating various genes involved in inflammation. NFκB has been casually implicated in various types of tumours [179]. Selective deletion of NFκB in hepatocytes or inhibition of TNF-α production by neighbouring parenchymal cells, induced programmed cell death of transformed hepatocytes and reduced the incidence of liver tumours. Paracrine activation of NF-κB in initiated cells was not important in the early stages of liver tumour development, but it was crucial for malignant conversion [180]. In colitis associated cancer model of mice, selective deletion of IKK-β in inflammatory cells that are surrounding the enterocytes reduced the mRNA of inflammatory cytokine levels and subsequently decreased the tumour formation. However, selective deletion of IKK-β in enterocytes did not reduce inflammatory features, but it induced enhanced cell death in enterocytes leading to a decrease in the incidence of colon cancer [181]. It is quite obvious from these experiments that NF-κB affects both tumour cells and inflammatory stromal cells to induce and promote cancer. NF-κB acts on enteroctyes to inhibit apoptosis and also acts on inflammatory cells to stimulate the secretion of various mediators of inflammation which inturn acts on the enteroctyes to induce cancer. However, in some tissues, NF-κB acts to prevent cancer. For example, inhibition of NF-κB in keratinocytes leads to squamous cell carcinoma of skin [182]. In MM, patient samples show a constitutive activation of NF-κB to a variable degree [183]. How these cells activate NF-κB in a constitutive manner is still under investigation. Soluble cytokines belonging to TNFα super family including TNF-α, BAFF,

strategy to inhibit IL-6 induced downstream signal transduction pathways [142].

migration of myeloma cells is also mediated by CXCL12 chemokine [123]. The expression of CXCR4 was higher in bone marrow plasma cells of patients with myeloma than patients with MGUS. Moreover, the bone marrow plasma of myeloma patients has higher SDF-1α levels than that of peripheral blood of myeloma cells and bone marrow plasma of healthy individuals [127]. Consistent with its effect on migration, invasion, homing, proliferation and survival, CXCL12/CXCR4 axis induced MAPK/ERK, AKT, PKC and NF-kB pathways [124, 127].

#### **4. Role of proinflammatory transcription factors**

#### **4.1 STAT3**

STAT3 is a member of the STAT family of transcription factors. STAT family proteins were first discovered in the context of the specificity of the IFN signalling [128]. STAT3 was first described as a DNA-binding factor, in IL-6 stimulated hepatocytes, capable of selectively interacting with an enhancer element in the promoter region of acute-phase genes [129].

STAT3 is constitutively phosphorylated in v-Src–transformed cells and has been found to be necessary for the v-Src induced carcinogenesis. Expression of a constitutively active version of STAT3 on its own can lead to fibroblast transformation, showing that STAT3 is an oncogene [130]. Consistent with its role in various cancers, STAT3 regulates various genes involved in different aspects of cancer progression. Genes regulated by STAT3 that are involved in proliferation and growth include c-myc, cyclinD3, cyclin A, cdc25a, p21, cyclinD1, Pim-1 and Pim-2. Genes regulated by STAT3 that are involved in survival include proteins belonging to the family of Bcl-2 and IAPs, namely, Bcl-2, Bcl-xL, Mcl-1 and survivin. STAT3 has also been shown to downregulate the Fas cytokine. STAT3 mediated angiogenesis is mediated by VEGF; STAT3 also regulates MMP family members MMP2 and MMP9 [131]. STAT3 is vital for development, seen from STAT3 knock out mice which succumb to embryonic lethality [132]. However, disruption of STAT3 function either by deleting the gene or by introducing the dominant negative form of STAT3, leads to only a few phenotypical changes [133]. These findings are critical for the development of therapeutic strategies with high therapeutic index. In MM, STAT3 plays an important role in survival. It upregulates anti-apoptotic proteins like Bcl2, Bcl-XL and Mcl-1 [134-136]. Constitutive expression of STAT3 confers myeloma cells resistance to apoptosis [137]. Out of all the anti-apoptotic proteins regulated by STAT3, Mcl-1 seems to be more important. While antisense inhibition of Bcl-xL did not inhibit survival, knock down of Mcl-1 was sufficient to inhibit survival in myeloma cells. Overexpression of Mcl-1 was able to promote proliferation of multiple myeloma cells lines, even in the absence of IL-6 [138].

Knock down of Bcl-2 can augment dexamethasone induced apoptosis [139], but again, the importance of STAT3 in regulating the anti-apoptotic proteins and thereby the survival of myeloma cells remains controversial in the light of a lack of correlation between the constitutive expression of STAT3 and the anti-apoptotic proteins [140]. However, it is clear that STAT3 is not the only factor which regulates the survival of myeloma cells because myeloma cells become independent of a IL-6-gp130-STAT3 pathway in the presence of bone marrow stromal cells [51]. Almost 48% of MM patients have constitutively activated STAT3 [140]. There has been no activating mutations of STAT3 detected in MM. But, there has been epigenetic silencing of negative regulators of STAT3, namely, SHP1 and SOCS in MM. 27 of 34 (79.4%) myeloma samples showed SHP1 hypermethylation. At least in U266 MM cells, methylation of SHP1 may be responsible for constitutive STAT3 activation, because treatment with 5-azacytidine, a DNA demethylator, led to a progressive demethylation of SHP1 and a parallel downregulation of phosphorylated STAT3 [15]. SOCS-1 is hypermethylated in 23 out of 35 (62.9%) MM patient samples and consistently expression of this protein is upregulated after treatment with demethylators. So, it can be concluded that suppression of the expression of negative regulators of IL6-JAK-S TAT pathway by epigenetic silencing increases the sensitivity of myeloma cells to IL-6 induced proliferation and survival [141]. Moreover, overexpression of SOCS using adenoviral vector inhibited the IL-6 induced proliferation in IL-6 dependent multiple myeloma cells, hinting at another strategy to inhibit IL-6 induced downstream signal transduction pathways [142].

There are lots of therapeutic strategies that are being developed to target JAK-STAT3 pathway in MM. In fact, the novel agents that are being used nowadays namely, thalidomide and its derivatives and bortezomib, act partially to disrupt the NF-κB induced activation of IL-6 and thereby STAT3 activation. Numerous drugs that inhibit IL-6-JAK-STAT3 pathway at various levels induce apoptosis, both in vitro and in vivo [143-175].

#### **4.2 NF-κB pathway**

102 Multiple Myeloma – An Overview

migration of myeloma cells is also mediated by CXCL12 chemokine [123]. The expression of CXCR4 was higher in bone marrow plasma cells of patients with myeloma than patients with MGUS. Moreover, the bone marrow plasma of myeloma patients has higher SDF-1α levels than that of peripheral blood of myeloma cells and bone marrow plasma of healthy individuals [127]. Consistent with its effect on migration, invasion, homing, proliferation and survival, CXCL12/CXCR4 axis induced MAPK/ERK, AKT, PKC and NF-kB pathways

STAT3 is a member of the STAT family of transcription factors. STAT family proteins were first discovered in the context of the specificity of the IFN signalling [128]. STAT3 was first described as a DNA-binding factor, in IL-6 stimulated hepatocytes, capable of selectively interacting with an enhancer element in the promoter region of acute-phase genes [129].

STAT3 is constitutively phosphorylated in v-Src–transformed cells and has been found to be necessary for the v-Src induced carcinogenesis. Expression of a constitutively active version of STAT3 on its own can lead to fibroblast transformation, showing that STAT3 is an oncogene [130]. Consistent with its role in various cancers, STAT3 regulates various genes involved in different aspects of cancer progression. Genes regulated by STAT3 that are involved in proliferation and growth include c-myc, cyclinD3, cyclin A, cdc25a, p21, cyclinD1, Pim-1 and Pim-2. Genes regulated by STAT3 that are involved in survival include proteins belonging to the family of Bcl-2 and IAPs, namely, Bcl-2, Bcl-xL, Mcl-1 and survivin. STAT3 has also been shown to downregulate the Fas cytokine. STAT3 mediated angiogenesis is mediated by VEGF; STAT3 also regulates MMP family members MMP2 and MMP9 [131]. STAT3 is vital for development, seen from STAT3 knock out mice which succumb to embryonic lethality [132]. However, disruption of STAT3 function either by deleting the gene or by introducing the dominant negative form of STAT3, leads to only a few phenotypical changes [133]. These findings are critical for the development of therapeutic strategies with high therapeutic index. In MM, STAT3 plays an important role in survival. It upregulates anti-apoptotic proteins like Bcl2, Bcl-XL and Mcl-1 [134-136]. Constitutive expression of STAT3 confers myeloma cells resistance to apoptosis [137]. Out of all the anti-apoptotic proteins regulated by STAT3, Mcl-1 seems to be more important. While antisense inhibition of Bcl-xL did not inhibit survival, knock down of Mcl-1 was sufficient to inhibit survival in myeloma cells. Overexpression of Mcl-1 was able to promote

proliferation of multiple myeloma cells lines, even in the absence of IL-6 [138].

Knock down of Bcl-2 can augment dexamethasone induced apoptosis [139], but again, the importance of STAT3 in regulating the anti-apoptotic proteins and thereby the survival of myeloma cells remains controversial in the light of a lack of correlation between the constitutive expression of STAT3 and the anti-apoptotic proteins [140]. However, it is clear that STAT3 is not the only factor which regulates the survival of myeloma cells because myeloma cells become independent of a IL-6-gp130-STAT3 pathway in the presence of bone marrow stromal cells [51]. Almost 48% of MM patients have constitutively activated STAT3 [140]. There has been no activating mutations of STAT3 detected in MM. But, there has been epigenetic silencing of negative regulators of STAT3, namely, SHP1 and SOCS in MM. 27 of

**4. Role of proinflammatory transcription factors** 

[124, 127].

**4.1 STAT3** 

NF-κB is a Rel family of transcription factors consisting of p50, p52, c-Rel, p65/RelA and RelB subunits [176, 177]. It was discovered by Dr. Baltimore and colleagues in 1986 as a DNA binding protein, recognising specific sequences in the immunoglobulin kappa light chain joining (J) segment gene region in B cells [178].

Various inflammatory stimuli activate the NF-κB pathway. There are two pathways involved in the activation of the NF-κB pathway: the classical pathway and the alternative pathway.

NF-κB is a main transcription factor regulating various genes involved in inflammation. NFκB has been casually implicated in various types of tumours [179]. Selective deletion of NFκB in hepatocytes or inhibition of TNF-α production by neighbouring parenchymal cells, induced programmed cell death of transformed hepatocytes and reduced the incidence of liver tumours. Paracrine activation of NF-κB in initiated cells was not important in the early stages of liver tumour development, but it was crucial for malignant conversion [180]. In colitis associated cancer model of mice, selective deletion of IKK-β in inflammatory cells that are surrounding the enterocytes reduced the mRNA of inflammatory cytokine levels and subsequently decreased the tumour formation. However, selective deletion of IKK-β in enterocytes did not reduce inflammatory features, but it induced enhanced cell death in enterocytes leading to a decrease in the incidence of colon cancer [181]. It is quite obvious from these experiments that NF-κB affects both tumour cells and inflammatory stromal cells to induce and promote cancer. NF-κB acts on enteroctyes to inhibit apoptosis and also acts on inflammatory cells to stimulate the secretion of various mediators of inflammation which inturn acts on the enteroctyes to induce cancer. However, in some tissues, NF-κB acts to prevent cancer. For example, inhibition of NF-κB in keratinocytes leads to squamous cell carcinoma of skin [182]. In MM, patient samples show a constitutive activation of NF-κB to a variable degree [183]. How these cells activate NF-κB in a constitutive manner is still under investigation. Soluble cytokines belonging to TNFα super family including TNF-α, BAFF,

Targeted Inhibition of Multiple Proinflammatory

tumour load and osteolytic lesions [193].

reviewed in detail in the following section.

**5.2 Vascular Endothelial Growth Factor (VEGF)** 

Signalling Pathways for the Prevention and Treatment of Multiple Myeloma 105

and thereby activation and inactivation of various biologically significant proteins like chemokines and growth factors. In the context of cancer, both the cancer cells and stromal cells secrete MMPs. Their involvement in invasion and metastasis was examined in various clinical models. Recent evidence suggests the role of MMPs in various hallmarks of cancer progression [190]. Culture supernatants of bone marrow derived stromal cells from multiple myeloma patients were found to have higher levels of MMP-1 and MMP-2 than control samples [191]. Moreover, endothelial cells secrete hepatocyte growth factor, which acts on myeloma cells to stimulate the secretion of MMP-9 [192]. 5T MM bone marrow expresses various MMPs, such as MMP2, MMP8, MMP9 and MMP13. Adequate inhibition of these MMPs by a broad spectrum MMP inhibitor SC-964 suppresses angiogenesis, reduces

VEGF is a signal protein that stimulates formation of new blood vessels, through vasculogenesis and angiogenesis. The activity of VEGF is mediated through three receptor tyrosine kinases: VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1) and VEGFR-3 [194]. Dysregulation of VEGF has been shown to be a major contributor to tumour angiogenesis as well, promoting tumour growth, invasion and metastasis [195]. Upon stimulation by VEGF, bovine capillary endothelial cells were shown to proliferate and show signs of capillary-like tube structures [196]. Significantly elevated levels of VEGF are observed in a variety of haematologic malignancies [197-201]. Several studies link VEGF inactivation to anti-tumour effects [202]. Angiogenesis appears to play a role in haematological malignancies [203]. There is growing evidence that increased bone marrow angiogenesis occurs in myeloma [204, 205] and is related to disease activity [206, 207]. Angiogenesis in myeloma also appears to be correlated with the Plasma Cell Labelling Index, PCLI [206]. Micro vessel density (MVD) increases five-to-six fold in magnitude with progression from gammopathy of undetermined significance (MGUS) or non-active MM to the active MM [93, 208]. Moreover, after chemotherapy, MVD decreases significantly in patients in complete or partial remission [209]. MM cells release angiogenic factors, such as FGF and VEGF [93, 210], and are shown to induce angiogenesis in vivo in the Chick Chorioallantoic Membrane assay [93]. They secrete matrix metalloproteinase-2 and -9 (MMP-2 and MMP-9) and urokinase-type plasminogen activator [93] and cytokines recruiting inflammatory cells, such as mast cells, that then induce angiogenesis through secretion of angiogenic factors in their granules [211]. A better understanding of some of the above angiogenic factors would help in developing novel therapeutic targets against MM. A few of the widely prominent angiogenic factors are

A number of studies implicate dysregulation of VEGF in MM pathogenesis and associated clinical features, including lytic lesions of the bone and immune deficiency. VEGF protein was found in malignant cells from 75% of MM patients studied [212]. Increased serum levels of VEGF have been correlated with a poor prognosis in patients with advanced stages of MM [213]. In fact, Iwasaki T et al. report predicting treatment responses and disease progression in myeloma using serum vascular endothelial growth factor [214]. Another patient study claims that the levels of VEGF, along with FGF, parallel disease activity [210]. VEGF may also affect the immune response in MM patients. Sera from MM patients' bone

APRIL, lymphotoxin b, are known to activate NF-κB and are present in the bone marrow microenvironment. Adhesion of myeloma cells to the bone marrow stromal cells and osteoclasts also activates the NF-κB pathway in both myeloma cells and osteoclasts, and bone marrow stromal cells.

Moreover, around 15-20% of myeloma samples and 40% of the cell lines show activating mutations in the NF-κB pathway [13, 184, 185]. There could be some unidentified genetic mutations or epigenetic modifications that might explain the constitutive activation in the remaining tumours. Gain of function mutations include ones encoding receptors known to activate NF-κB namely, CD40, LTβR, TAC1, NIK (NF-κB-inducing kinase), and direct mutations involving NF-κB1 p50/p105 and NF-κB2 p52/ p100. Loss of function mutations include those that involve negative regulators of NF-κB activation namely, TRAF3, TRAF2, CYLD and cIAP1/cIAP2, inactivation of TRAF3 being the most common. These mutations activate both classical and alternative pathways of NF-κB. CD40, LTβR, TAC1 and receptor overexpression may be sufficient to activate the NF-κB pathway or might enhance the sensitivity of MM cells to factors in the tumour microenvironment. Overexpression of NIK or NF-κB1 p105 directly leads to constitutive activation of NF-κB. Deletion of sequences in the p100 IκB-like domain of NF-ΚB2 promotes processing of p100 to p52 and activation of the alternative NF-κB pathway [184, 185]. Activating mutations of the NF-κB pathway helps the myeloma cells become independent of the bone marrow, as they overcome the need for external cytokines activating the pathway [13].

Activation of NF-κB in myeloma cells induces proliferation, survival and chemoresistance. When compared to chemosensitive myeloma cell lines, chemoresistant myeloma cells express higher levels of NF-κB, suggesting a link between NF-κB and development of chemoresistance [186, 187]. Moreover, dexamethasone induced apoptosis is associated with a decrease in the NF-κB DNA binding activity. Interestingly, NF-κB can also serve as a prognostic indicator for response to dexamethasone. Only patients who responded to dexamethasone, demonstrated decreased NF-κB DNA binding activity in their samples. Enforced ectopic expression of Bcl-2 in myeloma cells conferred resistance to dexamethasone induced apoptosis, and this was also associated with enhanced NF-κB DNA binding [187]. Inhibition of NF-κB by IKK inhibitor abrogates the protective effect of IL-6 on dexamethesone induced apoptosis. It also potentiated TNFα induced apoptosis in myeloma cells. NF-κB inhibition abrogated the TNFα induced upregulation of ICAM-1, both in myeloma cells and in bone marrow stromal cells. It also inhibited the myeloma cell adhesion induced IL-6 secretion by bone marrow stromal cells and resulting proliferation of myeloma cells. These findings indicate that pro-survival functions of the bone marrow microenvironment are abrogated upon NF-κB inhibition. The novel therapeutic agents namely, bortezomib and thalidomide and its derivatives, act at least partially by inhibiting NF-κB [188].

#### **5. Role of matrix proteinases, angiogneic and adhesion molecules**

#### **5.1 Matrix metalloproteinase**

Matrix metalloproteinase belong to a family of proteases, capable of degrading all kinds of extracellular matrix proteins. In 1962, Gross et al. discovered MMP, when they found collagenase activity in the tail of a tadpole during metamorphogenesis [189]. These proteins function not only to remodel the extracellular matrix, but also are involved in the cleavage

APRIL, lymphotoxin b, are known to activate NF-κB and are present in the bone marrow microenvironment. Adhesion of myeloma cells to the bone marrow stromal cells and osteoclasts also activates the NF-κB pathway in both myeloma cells and osteoclasts, and

Moreover, around 15-20% of myeloma samples and 40% of the cell lines show activating mutations in the NF-κB pathway [13, 184, 185]. There could be some unidentified genetic mutations or epigenetic modifications that might explain the constitutive activation in the remaining tumours. Gain of function mutations include ones encoding receptors known to activate NF-κB namely, CD40, LTβR, TAC1, NIK (NF-κB-inducing kinase), and direct mutations involving NF-κB1 p50/p105 and NF-κB2 p52/ p100. Loss of function mutations include those that involve negative regulators of NF-κB activation namely, TRAF3, TRAF2, CYLD and cIAP1/cIAP2, inactivation of TRAF3 being the most common. These mutations activate both classical and alternative pathways of NF-κB. CD40, LTβR, TAC1 and receptor overexpression may be sufficient to activate the NF-κB pathway or might enhance the sensitivity of MM cells to factors in the tumour microenvironment. Overexpression of NIK or NF-κB1 p105 directly leads to constitutive activation of NF-κB. Deletion of sequences in the p100 IκB-like domain of NF-ΚB2 promotes processing of p100 to p52 and activation of the alternative NF-κB pathway [184, 185]. Activating mutations of the NF-κB pathway helps the myeloma cells become independent of the bone marrow, as they overcome the need for

Activation of NF-κB in myeloma cells induces proliferation, survival and chemoresistance. When compared to chemosensitive myeloma cell lines, chemoresistant myeloma cells express higher levels of NF-κB, suggesting a link between NF-κB and development of chemoresistance [186, 187]. Moreover, dexamethasone induced apoptosis is associated with a decrease in the NF-κB DNA binding activity. Interestingly, NF-κB can also serve as a prognostic indicator for response to dexamethasone. Only patients who responded to dexamethasone, demonstrated decreased NF-κB DNA binding activity in their samples. Enforced ectopic expression of Bcl-2 in myeloma cells conferred resistance to dexamethasone induced apoptosis, and this was also associated with enhanced NF-κB DNA binding [187]. Inhibition of NF-κB by IKK inhibitor abrogates the protective effect of IL-6 on dexamethesone induced apoptosis. It also potentiated TNFα induced apoptosis in myeloma cells. NF-κB inhibition abrogated the TNFα induced upregulation of ICAM-1, both in myeloma cells and in bone marrow stromal cells. It also inhibited the myeloma cell adhesion induced IL-6 secretion by bone marrow stromal cells and resulting proliferation of myeloma cells. These findings indicate that pro-survival functions of the bone marrow microenvironment are abrogated upon NF-κB inhibition. The novel therapeutic agents namely, bortezomib and thalidomide and its derivatives, act at least

**5. Role of matrix proteinases, angiogneic and adhesion molecules** 

Matrix metalloproteinase belong to a family of proteases, capable of degrading all kinds of extracellular matrix proteins. In 1962, Gross et al. discovered MMP, when they found collagenase activity in the tail of a tadpole during metamorphogenesis [189]. These proteins function not only to remodel the extracellular matrix, but also are involved in the cleavage

bone marrow stromal cells.

external cytokines activating the pathway [13].

partially by inhibiting NF-κB [188].

**5.1 Matrix metalloproteinase** 

and thereby activation and inactivation of various biologically significant proteins like chemokines and growth factors. In the context of cancer, both the cancer cells and stromal cells secrete MMPs. Their involvement in invasion and metastasis was examined in various clinical models. Recent evidence suggests the role of MMPs in various hallmarks of cancer progression [190]. Culture supernatants of bone marrow derived stromal cells from multiple myeloma patients were found to have higher levels of MMP-1 and MMP-2 than control samples [191]. Moreover, endothelial cells secrete hepatocyte growth factor, which acts on myeloma cells to stimulate the secretion of MMP-9 [192]. 5T MM bone marrow expresses various MMPs, such as MMP2, MMP8, MMP9 and MMP13. Adequate inhibition of these MMPs by a broad spectrum MMP inhibitor SC-964 suppresses angiogenesis, reduces tumour load and osteolytic lesions [193].

#### **5.2 Vascular Endothelial Growth Factor (VEGF)**

VEGF is a signal protein that stimulates formation of new blood vessels, through vasculogenesis and angiogenesis. The activity of VEGF is mediated through three receptor tyrosine kinases: VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1) and VEGFR-3 [194]. Dysregulation of VEGF has been shown to be a major contributor to tumour angiogenesis as well, promoting tumour growth, invasion and metastasis [195]. Upon stimulation by VEGF, bovine capillary endothelial cells were shown to proliferate and show signs of capillary-like tube structures [196]. Significantly elevated levels of VEGF are observed in a variety of haematologic malignancies [197-201]. Several studies link VEGF inactivation to anti-tumour effects [202]. Angiogenesis appears to play a role in haematological malignancies [203]. There is growing evidence that increased bone marrow angiogenesis occurs in myeloma [204, 205] and is related to disease activity [206, 207]. Angiogenesis in myeloma also appears to be correlated with the Plasma Cell Labelling Index, PCLI [206]. Micro vessel density (MVD) increases five-to-six fold in magnitude with progression from gammopathy of undetermined significance (MGUS) or non-active MM to the active MM [93, 208]. Moreover, after chemotherapy, MVD decreases significantly in patients in complete or partial remission [209]. MM cells release angiogenic factors, such as FGF and VEGF [93, 210], and are shown to induce angiogenesis in vivo in the Chick Chorioallantoic Membrane assay [93]. They secrete matrix metalloproteinase-2 and -9 (MMP-2 and MMP-9) and urokinase-type plasminogen activator [93] and cytokines recruiting inflammatory cells, such as mast cells, that then induce angiogenesis through secretion of angiogenic factors in their granules [211]. A better understanding of some of the above angiogenic factors would help in developing novel therapeutic targets against MM. A few of the widely prominent angiogenic factors are reviewed in detail in the following section.

A number of studies implicate dysregulation of VEGF in MM pathogenesis and associated clinical features, including lytic lesions of the bone and immune deficiency. VEGF protein was found in malignant cells from 75% of MM patients studied [212]. Increased serum levels of VEGF have been correlated with a poor prognosis in patients with advanced stages of MM [213]. In fact, Iwasaki T et al. report predicting treatment responses and disease progression in myeloma using serum vascular endothelial growth factor [214]. Another patient study claims that the levels of VEGF, along with FGF, parallel disease activity [210]. VEGF may also affect the immune response in MM patients. Sera from MM patients' bone

Targeted Inhibition of Multiple Proinflammatory

has been studied for cancer therapy.

**5.3 Adhesion molecules** 

Signalling Pathways for the Prevention and Treatment of Multiple Myeloma 107

pathways range from small molecule VEGF/VEGFR inhibitors, anti-VEGF and anti-VEGF receptor antibodies, such as bevacizumab [244, 245], and VEGF transcription inhibitors. Of interest are various kinase inhibitors that block the signal transduction mediated by VEGF. The VEGF receptor tyrosine kinase inhibitor PTK787 is active preclinically and undergoing clinical protocol testing in MM [246, 247]. It acts directly on MM cells to inhibit VEGFinduced MM cell growth and migration, and inhibits paracrine IL-6–mediated MM cell growth in the BM milieu. Pazopanib [248], another VEGF receptor tyrosine kinase inhibitor,

Cell adhesion is a key physiological event involved in morphogenesis and histogenesis. Adhesion molecules mediate cell-cell and cell-ECM interactions [249], and are also involved in intracellular signalling after engagement with their receptors. Broadly, there are five groups of adhesion molecules. They are 1) the integrins-mediating cell-ECM and cell-cell adhesion 2) the cadherin family-mediating homotypic cell-cell adhesion 3) the selectin family-mediating heterotypic cell-cell adhesion 4) the immunoglobulin superfamily-mediating cell-cell adhesion and 5) other transmembrane proteoglycans, such as CD44 adhesion molecules and syndecan that mediate cell-extracellular matrix adhesion [12]. Dysregulated expression or function of

In MM, there is evidence that adhesion molecules mediate homing of MM cells to the bone marrow, secretion of cytokines and growth factors, and development of chemoresistance. Out of all the adhesion molecules, VLA-4 and VLA-5 expressed by the myeloma cells play a crucial role in the myeloma pathogenesis [250]. VCAM-1 and fibronectin are the receptors for VLA. VLA adheres to the bone marrow stromal cells by binding to VCAM, CS-1 fragment and H1 region of fibronectin [251]. Inhibition of VLA using blocking antibodies inhibit the adhesion of myeloma cells to the bone marrow stromal cells and fibronectin [252]. VLA dependent adhesion to the bone marrow is regulated by the CXCL12/CXCR4 axis [253]. This is further supported by the finding that disruption of CXCL12/CXCR4 axis results in downregulation of VLA-4 and decreased adhesive capacity in the mobilised myeloma cells when compared to premobilisation bone marrow myeloma cells [126].

VLA dependent adhesion of MM cells to the bone marrow stromal cells induces secretion of IL-6 by an NF-κB mediated mechanism [38, 39]. Drug-sensitive 8226 human myeloma cells, expressing both VLA-4 and VLA-5 receptors, are relatively resistant to the apoptotic effects of doxorubicin and melphalan, when pre-adhered to FN and compared with cells grown in suspension. Upon exposure to chemotherapeutic agents, myeloma cells expressing high levels of VLA-4 have survival advantage over those that express them at low levels. When the cells were removed from a chronic drug exposure, the VLA-4 expression decreased. However, there was no upregulation of common mediators of drug resistance like anti-apoptotic proteins and drug exporting glycoproteins in the cells. It was concluded that though the survival advantage offered by VLA-4 induced adhesion to fibronectin is less, it is significant in helping them survive the acute drug exposure and gives them adequate time to employ the classic mechanisms of drug resistance [254]. How adhesion of cells to fibronecin is rendering the cells resistance to chemotherapy, is still not completely understood. It was shown that adhesion of myeloma cells to fibronectin activates NF-κB and its regulated gene products, leading to drug resistance [255]. Moreover, it seems that IL-6 and fibronectin collaborate to stimulate STAT3

adhesion molecules are involved in various steps of cancer progression.

and fibronectin augments IL-6 induced STAT3 activation [256].

marrow inhibits antigen presentation by dendritic cells (DCs); conversely, anti-VEGF antibodies neutralized this inhibitory effect, confirming that VEGF mediates immunosuppression in MM patients [215]. The cytokine is probably involved in the progression of MM to plasma cell leukaemia (PCL) [216]. Not just the ligand, its receptor VEGFR-1 is also widely expressed on both MM cell lines and patient MM cells, confirmed both by reverse-transcriptase polymerase chain reaction (RT-PCR) analyses and immunoprecipitation [217-219]. VEGF is generally present in the bone marrow (BM) microenvironment of patients with MM and associated with neovascularization at sites of MM cell infiltration [220]. The induction of VEGF enhances the microvascular density of bone marrow and accounts for the abnormal structure of myeloma tumour vessels [221]http://www.nejm.org.libproxy1.nus.edu.sg/doi/full/10.1056/NEJMra1011442 - ref12. VEGF increases both osteoclastic bone-resorbing activity [222] and osteoclast chemotaxis [223], and inhibits maturation of dendritic cells [224]. As marrow neovascularization parallels disease activity in MM, it is reasonable to postulate that the vascular growth factor is acting in an autocrine fashion. However, MM cells express VEGF receptors only weakly, if at all. Therefore, the mechanism may be paracrine and result from a VEGF-induced time and dose-dependent increase in stromal cell secretion of interleukin-6 (IL-6), a known MM growth factor [225]. Another cytokine, TNFα, has been reported to be involved in the control of VEGF production by myeloma cells [226]. Moreover, VEGF directly, or indirectly through its stimulatory activity on TNF-α and IL-β1, stimulates the activation of osteoclasts and thus contributes to the lytic lesions in MM [222].

Other factors modulating VEGF secretion include Interleukins: IL-1β [227], IL-10 and IL-13 [228]; secretion of IL-6 [218, 225, 229] or VEGF by both BMSCs and tumour cells (paracrine/autocrine loop); hypoxia and the presence of mutant oncogenes (i.e., mutant Ras [mutRas] or Bcr-Abl, which up-regulate VEGF expression via HIF-1α protein); secretion of growth factors, such as insulin-like growth factor-1 (IGF-1) [88, 230], fibroblast growth factor- 4 (FGF-4) [231], platelet-derived growth factor (PDGF) [232], TGF-β [233], TNF-α [234] and gonadotropins [235]; c-maf–driven expression of tumour integrin β7 [236]; tumour cell expression of ICAM1 and LFA1 modulating adhesion to ECM and BMSCs, thereby increasing VEGF production and secretion; and CD40 activation, which induces p53 dependent VEGF secretion. Binding of VEGF to MM cells triggers VEGFR tyrosine phosphorylation, activating several downstream signalling pathways, particularly involving phosphatidyl-inositol-3 kinase [237, 238]. PI3-kinase- dependent cascade mediates MM cell migration on fibronectin, evidenced by using the PI3-kinase inhibitor bis-indolylmaleimide I and LY294002 [237]. This signal transduction pathway is mediated by focal adhesion proteins [239], such as FAK, paxillin and cortactin, which are responsible for the stabilization of focal adhesion plaques and the reorganization of actin fibres [240]. VEGF also regulates MM cell survival by modulating the expression of Mcl-1 and survivin [241].

MAP kinases (MAPK) are the final effectors of the signal to the nucleus, thereby activating genes for proliferation, migration and survival [242]. This increased migration and cell proliferation is because of the activation of VEGFR-2, since it is totally inhibited by a VEGFR-2 blocking antibody [243]. In fact, MEK-extracellular signal-regulated protein kinase (ERK) pathway is shown to mediate MM cell proliferation, evidenced by use of anti-VEGF antibody and PD098059 [217]. Approaches to disrupt the VEGF/VEGF receptor signalling pathways range from small molecule VEGF/VEGFR inhibitors, anti-VEGF and anti-VEGF receptor antibodies, such as bevacizumab [244, 245], and VEGF transcription inhibitors. Of interest are various kinase inhibitors that block the signal transduction mediated by VEGF. The VEGF receptor tyrosine kinase inhibitor PTK787 is active preclinically and undergoing clinical protocol testing in MM [246, 247]. It acts directly on MM cells to inhibit VEGFinduced MM cell growth and migration, and inhibits paracrine IL-6–mediated MM cell growth in the BM milieu. Pazopanib [248], another VEGF receptor tyrosine kinase inhibitor, has been studied for cancer therapy.

#### **5.3 Adhesion molecules**

106 Multiple Myeloma – An Overview

marrow inhibits antigen presentation by dendritic cells (DCs); conversely, anti-VEGF antibodies neutralized this inhibitory effect, confirming that VEGF mediates immunosuppression in MM patients [215]. The cytokine is probably involved in the progression of MM to plasma cell leukaemia (PCL) [216]. Not just the ligand, its receptor VEGFR-1 is also widely expressed on both MM cell lines and patient MM cells, confirmed both by reverse-transcriptase polymerase chain reaction (RT-PCR) analyses and immunoprecipitation [217-219]. VEGF is generally present in the bone marrow (BM) microenvironment of patients with MM and associated with neovascularization at sites of MM cell infiltration [220]. The induction of VEGF enhances the microvascular density of bone marrow and accounts for the abnormal structure of myeloma tumour vessels [221]http://www.nejm.org.libproxy1.nus.edu.sg/doi/full/10.1056/NEJMra1011442 - ref12. VEGF increases both osteoclastic bone-resorbing activity [222] and osteoclast chemotaxis [223], and inhibits maturation of dendritic cells [224]. As marrow neovascularization parallels disease activity in MM, it is reasonable to postulate that the vascular growth factor is acting in an autocrine fashion. However, MM cells express VEGF receptors only weakly, if at all. Therefore, the mechanism may be paracrine and result from a VEGF-induced time and dose-dependent increase in stromal cell secretion of interleukin-6 (IL-6), a known MM growth factor [225]. Another cytokine, TNFα, has been reported to be involved in the control of VEGF production by myeloma cells [226]. Moreover, VEGF directly, or indirectly through its stimulatory activity on TNF-α and IL-β1, stimulates the activation of osteoclasts and thus

Other factors modulating VEGF secretion include Interleukins: IL-1β [227], IL-10 and IL-13 [228]; secretion of IL-6 [218, 225, 229] or VEGF by both BMSCs and tumour cells (paracrine/autocrine loop); hypoxia and the presence of mutant oncogenes (i.e., mutant Ras [mutRas] or Bcr-Abl, which up-regulate VEGF expression via HIF-1α protein); secretion of growth factors, such as insulin-like growth factor-1 (IGF-1) [88, 230], fibroblast growth factor- 4 (FGF-4) [231], platelet-derived growth factor (PDGF) [232], TGF-β [233], TNF-α [234] and gonadotropins [235]; c-maf–driven expression of tumour integrin β7 [236]; tumour cell expression of ICAM1 and LFA1 modulating adhesion to ECM and BMSCs, thereby increasing VEGF production and secretion; and CD40 activation, which induces p53 dependent VEGF secretion. Binding of VEGF to MM cells triggers VEGFR tyrosine phosphorylation, activating several downstream signalling pathways, particularly involving phosphatidyl-inositol-3 kinase [237, 238]. PI3-kinase- dependent cascade mediates MM cell migration on fibronectin, evidenced by using the PI3-kinase inhibitor bis-indolylmaleimide I and LY294002 [237]. This signal transduction pathway is mediated by focal adhesion proteins [239], such as FAK, paxillin and cortactin, which are responsible for the stabilization of focal adhesion plaques and the reorganization of actin fibres [240]. VEGF also regulates MM cell survival by modulating the expression of Mcl-1 and survivin [241]. MAP kinases (MAPK) are the final effectors of the signal to the nucleus, thereby activating genes for proliferation, migration and survival [242]. This increased migration and cell proliferation is because of the activation of VEGFR-2, since it is totally inhibited by a VEGFR-2 blocking antibody [243]. In fact, MEK-extracellular signal-regulated protein kinase (ERK) pathway is shown to mediate MM cell proliferation, evidenced by use of anti-VEGF antibody and PD098059 [217]. Approaches to disrupt the VEGF/VEGF receptor signalling

contributes to the lytic lesions in MM [222].

Cell adhesion is a key physiological event involved in morphogenesis and histogenesis. Adhesion molecules mediate cell-cell and cell-ECM interactions [249], and are also involved in intracellular signalling after engagement with their receptors. Broadly, there are five groups of adhesion molecules. They are 1) the integrins-mediating cell-ECM and cell-cell adhesion 2) the cadherin family-mediating homotypic cell-cell adhesion 3) the selectin family-mediating heterotypic cell-cell adhesion 4) the immunoglobulin superfamily-mediating cell-cell adhesion and 5) other transmembrane proteoglycans, such as CD44 adhesion molecules and syndecan that mediate cell-extracellular matrix adhesion [12]. Dysregulated expression or function of adhesion molecules are involved in various steps of cancer progression.

In MM, there is evidence that adhesion molecules mediate homing of MM cells to the bone marrow, secretion of cytokines and growth factors, and development of chemoresistance. Out of all the adhesion molecules, VLA-4 and VLA-5 expressed by the myeloma cells play a crucial role in the myeloma pathogenesis [250]. VCAM-1 and fibronectin are the receptors for VLA. VLA adheres to the bone marrow stromal cells by binding to VCAM, CS-1 fragment and H1 region of fibronectin [251]. Inhibition of VLA using blocking antibodies inhibit the adhesion of myeloma cells to the bone marrow stromal cells and fibronectin [252]. VLA dependent adhesion to the bone marrow is regulated by the CXCL12/CXCR4 axis [253]. This is further supported by the finding that disruption of CXCL12/CXCR4 axis results in downregulation of VLA-4 and decreased adhesive capacity in the mobilised myeloma cells when compared to premobilisation bone marrow myeloma cells [126].

VLA dependent adhesion of MM cells to the bone marrow stromal cells induces secretion of IL-6 by an NF-κB mediated mechanism [38, 39]. Drug-sensitive 8226 human myeloma cells, expressing both VLA-4 and VLA-5 receptors, are relatively resistant to the apoptotic effects of doxorubicin and melphalan, when pre-adhered to FN and compared with cells grown in suspension. Upon exposure to chemotherapeutic agents, myeloma cells expressing high levels of VLA-4 have survival advantage over those that express them at low levels. When the cells were removed from a chronic drug exposure, the VLA-4 expression decreased. However, there was no upregulation of common mediators of drug resistance like anti-apoptotic proteins and drug exporting glycoproteins in the cells. It was concluded that though the survival advantage offered by VLA-4 induced adhesion to fibronectin is less, it is significant in helping them survive the acute drug exposure and gives them adequate time to employ the classic mechanisms of drug resistance [254]. How adhesion of cells to fibronecin is rendering the cells resistance to chemotherapy, is still not completely understood. It was shown that adhesion of myeloma cells to fibronectin activates NF-κB and its regulated gene products, leading to drug resistance [255]. Moreover, it seems that IL-6 and fibronectin collaborate to stimulate STAT3 and fibronectin augments IL-6 induced STAT3 activation [256].

Targeted Inhibition of Multiple Proinflammatory

analogues

**VEGF** CHIR-12.12 (Human

JB-1

 **CXCL12** 4F-benzoyl-TN14003 AMD3100 Thalidomide

antibody) Bevacizumab

**TNFα** Rituximab

**IGF** α-IR3

**STAT3** AR-42

**BAFF & APRIL** 

*Pharmacological/ Biological Blockers* 

Thalidomide and its

anti-CD40 antagonist

PTK787/ZK222584, SU6668, SU5416 Sorafenib

NVP-ADW742

Atiprimod Auranofin Avicin D Azaspirane AZD1480 Baicalein

Betulinic acid

Cantharidin Capsaicin

Celastrol

Butein

Signalling Pathways for the Prevention and Treatment of Multiple Myeloma 109

monoclonal antibody

Atacicept blocks the binding of BAFF and APRIL [268]

monoclonal antibody

secretion

inhibitors

IGF-1R

**TGF-β** SD-208 TGF-β receptor I kinase inhibitor [278]

antagonist

CXCR4 antoganist

CXCR4 inhibitor

inhibits STAT3 JAK-2 inhibitor Inhibits IL-6-mediated

JAK1 and JAK2

phosphorylation upregulates SHP-1

1

JAK1

CXCL12 and CXCR4

downregulates gp130 inhibits STAT3 activation inhibits activation of JAK2 activates protein phosphatase-1

suppresses the expression of TNFα

inhibits CD-40 enhanced VEGF

humanized murine anti--VEGF

VEGF receptor tyrosine kinase

IGF-1 like competitive peptide

IGF-1R tyrosine kinase inhibitor

immnunomodulator- downregulates

phosphorylation of signalling proteins inhibits the activation of Src kinase,

inhibits the activation of Src kinase, JAK1 and JAK2; and upregulates SHP-

inhibits phosphorylation of STAT3 inhibits the activation of Src kinase,

inhibits JAK2 and Src kinase

dual Raf kinase/VEGF-R inhibitor

neutralizing monoclonal antibody to

*Mechanism(s) of Action* **References** 

[266] [267]

[259]

[269]

[273]

[274]

[277]

[279]

[175] [143] [162] [282] [283] [174] [157]

[165]

[164]

[172] [146]

[284]

[267, 280] [281]

[275, 276]

[203, 270-272]

Fig. 1. Comprehensive representation of the role(s) of various inflammatory mediators in MM


BAFF IL-6 osteopontin

APRIL VEGF

SDF1α IL-6 BAFF APRIL IGF-1 TGF-β

TNF-α TGF-β VEGF

Fig. 1. Comprehensive representation of the role(s) of various inflammatory mediators

mAb

antibody

secretion

FGF

**Osteoclasts**

SDF1α IL-6 VEGF

*Pharmacological/ Biological Blockers* 

Bortezomib

antibody) CNTO 328 (siltuximab) ITF2357 histone deacetylase inhibitor Novel indolinone BIBF

1000 Sant7

6-amino-4-quinazoline

CHIR-12.12 (Human anti-CD40 antagonist

VEGF

**Endothelial Cell** 

in MM

**IL-6** 1339

**Myeloma Cell** 

Proliferation

NF-kB Survival/Drug resistance

Antiapoptosis/Proliferation

Survival/Proliferation

**Bone Marrow Stromal Cell** 

[257]

[166]

[258] [259]

[260-262]

[263]

[264]

[265]

VLA VCAM

*Mechanism(s) of Action* **References** 

high-affinity fully humanized anti-IL-6

inhibits CD-40 enhanced IL-6 secretion

inhibits IL-6 signalling

downregulates gp130

receptor α (CD126)

IL-6 neutralizing monoclonal

abrogates stroma-derived IL-6

IL-6 receptor superantagonist

down-modulates the interleukin-6

JAK2/STAT3

RAF/MEK/Erk

PI3K/AkT


Targeted Inhibition of Multiple Proinflammatory

SST0001

QLT0267

multiple signalling pathways offers better effects.

**Integrins** Anti-alpha4 Ab

**MMPs** Chitosan

mediators in MM

**6. Conclusions** 

**7. Acknowledgements** 

[Grant R-184-000-201-275] to GS.

144(5): p. 646-674.

**8. References** 

*Pharmacological/ Biological Blockers* 

Signalling Pathways for the Prevention and Treatment of Multiple Myeloma 111

p65

integrin

Table 1. List of various pharmacological/biological agents modulating inflammatory

Understanding the various growth and survival pathways activated in both myeloma cells and various components of the bone marrow microenvironment is of paramount importance, not only to the basic understanding of the biology of MM, but also to effectively produce efficacious and safer anti-myeloma agents. In essence, myeloma is initiated by the primary genetic abnormalities and supported by the bone marrow microenvironment induced growth and survival. The secondary genetic mutations and epigenetic abnormalities emancipate myeloma cells of their dependence on the bone marrow microenvironment, which is when they progress to extramedullary MM. There are multiple signalling pathways activated, which serve overlapping functions. Combined inhibition of

This work was supported by grants from the National Medical Research Council of Singapore [Grant R-713-000-124-213] and Cancer Science Institute of Singapore, Experimental Therapeutics I Program [Grant R-713-001-011-271] to APK; NUS Academic Research Fund [Grants R-184-000-170-112 and R-184-000-177-112], National kidney Foundation [Grant R-184-000-196-592] and National Medical Research Council of Singapore

[2] Agarwal, J.R. and W. Matsui, *Multiple myeloma: A paradigm for translation of the cancer stem cell hypothesis.* Anti-Cancer Agents in Medicinal Chemistry, 2010. 10(2): p. 116-120. [3] Colotta, F., et al., *Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic* 

[4] Hanahan, D. and R.A. Weinberg, *Hallmarks of cancer: The next generation.* Cell, 2011.

[1] Raab, M.S., et al., *Multiple myeloma.* The Lancet, 2009. 374(9686): p. 324-339.

*instability.* Carcinogenesis, 2009. 30(7): p. 1073-1081.

*Mechanism(s) of Action* **References** 

[293]

[294]

[295, 296]

[297297]

the phosphorylation of IκBα and of

a marine phospholipid that inhibits the activity of MMP-2 and MMP-9 a chemically modified heparin with

monoclonal antibody to alpha4

integrin-linked kinase inhibitor

antiheparanase activity



Table 1. List of various pharmacological/biological agents modulating inflammatory mediators in MM

#### **6. Conclusions**

110 Multiple Myeloma – An Overview

STAT3 phosphorylation inhibits activation of JAK2

inhibits the activation of c-src

upregulates PTEN inhibitor of JAK-2

of SHP-1 and PTEN JAK1/2 selective inhibitor Janus kinase inhibitor

SHP-1

1

*Mechanism(s) of Action* **References** 

[167] [145]

[150] [149] [161] [152] [172]

[151]

[155] [285] [142]

[173]

[163]

[286]

[169] [287]

[171] [154] [148] [168]

[288]

[283]

[289] [284]

[183] [290]

[291] [292] [287]

inhibits constitutive and IL-6-inducible

induces protein tyrosine phosphatase

inhibits the activation of c-src and JAK-2 and upregulates the expression

forced overexpression of SOCS

inhibits Aurora kinase A, Aurora kinase B, and Janus kinase 2/3 reduces Jak kinase autophosphorylation

induces the expression of the protein

inhibits of c-Src and JAK2 activation JAK2 tyrosine kinase inhibitor inhibits the activation of Src kinase, JAK1 and JAK2, and upregulates SHP-

tyrosine phosphatase, SHP-1 pan-Janus-activated kinase inhibitor inhibits both constitutive and IL-6 induced activation of STAT3 inhibits activation JAK2

inhibits both NF-κB nuclear translocation and DNA binding

suppresses NF-κB activation

pharmacological NF-κB inhibitors inhibits JAK2 and Src kinase

suppresses constitutively active NF-κB

suppresses constitutively active NF-κB through inhibition of IκBα kinase and

inhibits IκBα NFκB- p65 phosphorylation TNF-α

phosphorylation

IκB kinase β inhibitor suppresses NF-κB activation

*Pharmacological/ Biological Blockers* 

Compound K Curcumin

Decursin Embelin Emodin Genipin Guggulsterone

Icariside II

INCB16562 INCB20

Plumbagin

Pyridone 6 Resveratrol

TG101209 Thymoquinone Tyrphostin AG490 Ursolic acid

Azaspirane

Bay 11-7082 Celastrol

Curcumin Genistein

MLN120B Parthenolide Resveratrol

**NF-B** Azacitidine

SOCS

Infectivity-enhanced adenoviral vector of

Multitargeted kinase inhibitor, AT9283 Nifuroxazide

Understanding the various growth and survival pathways activated in both myeloma cells and various components of the bone marrow microenvironment is of paramount importance, not only to the basic understanding of the biology of MM, but also to effectively produce efficacious and safer anti-myeloma agents. In essence, myeloma is initiated by the primary genetic abnormalities and supported by the bone marrow microenvironment induced growth and survival. The secondary genetic mutations and epigenetic abnormalities emancipate myeloma cells of their dependence on the bone marrow microenvironment, which is when they progress to extramedullary MM. There are multiple signalling pathways activated, which serve overlapping functions. Combined inhibition of multiple signalling pathways offers better effects.

#### **7. Acknowledgements**

This work was supported by grants from the National Medical Research Council of Singapore [Grant R-713-000-124-213] and Cancer Science Institute of Singapore, Experimental Therapeutics I Program [Grant R-713-001-011-271] to APK; NUS Academic Research Fund [Grants R-184-000-170-112 and R-184-000-177-112], National kidney Foundation [Grant R-184-000-196-592] and National Medical Research Council of Singapore [Grant R-184-000-201-275] to GS.

#### **8. References**


Targeted Inhibition of Multiple Proinflammatory

1989. 84(6): p. 2008-2011.

2484-2491.

Research, 1992. 16(10): p. 951-959.

Signalling Pathways for the Prevention and Treatment of Multiple Myeloma 113

[24] Adachi, Y., N. Yoshio-Hoshino, and N. Nishimoto, *The blockade of IL-6 signaling in rational drug design.* Current Pharmaceutical Design, 2008. 14(12): p. 1217-1224. [25] Barut, B.A., et al., *Role of interleukin 6 in the growth of myeloma-derived cell lines.* Leukemia

[26] Hilbert, D.M., et al., *Interleukin 6 is essential for in vivo development of B lineage neoplasms.*

[27] Pulkki, K., et al., *Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma.*

[28] Kyrtsonis, M.C., et al., *Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma.* British Journal of Haematology, 1996. 93(2): p. 398-400. [29] Stasi, R., et al., *The prognostic value of soluble interleukin-6 receptor in patients with multiple* 

[30] Pelliniemi, T.T., et al., *Immunoreactive interleukin-6 and acute phase proteins as prognostic* 

[31] Bataille, R., et al., *Serum levels of interleukin 6, a potent myeloma cell growth factor, as a* 

[32] Bataille, R., et al., *Serum levels of interleukin 6, a potent myeloma cell growth factor, as a* 

[33] Kawano, M., et al., *Autocrine generation and requirement of BSF-2/IL-6 for human multiple* 

[34] Anderson, K.C., et al., *Response patterns of purified myeloma cells to hematopoietic growth* 

[35] Caligaris-Cappio, F., et al., *'Role of bone marrow stromal cells in the growth of human* 

[36] Klein, B., et al., *Paracrine rather than autocrine regulation of myeloma-cell growth and* 

[37] Lichtenstein, A., et al., *Production of cytokines by bone marrow cells obtained from patients* 

[38] Uchiyama, H., et al., *Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion.* Blood, 1993. 82(12): p. 3712-3720. [39] Chauhan, D., et al., *Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB.* Blood, 1996. 87(3): p. 1104-1112. [40] Abe, M., et al., *Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: A* 

[41] Ogata, A., et al., *IL-6 triggers cell growth via the ras-dependent mitogen-activated protein* 

[42] Croonquist, P.A., et al., *Gene profiling of a myeloma cell line reveals similarities and unique* 

[43] Chauhan, D., et al., *Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells.* Blood, 1997. 89(1): p. 227-234. [44] Chauhan, D., et al., *RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma* 

*kinase cascade.* Journal of Immunology, 1997. 159(5): p. 2212-2221.

*vicious cycle between bone destruction and myeloma expansion.* Blood, 2004. 104(8): p.

*signatures among IL-6 response, N-ras-activating mutations, and coculture with bone* 

*reflection of disease severity in plasma cell dyscrasias.* Journal of Clinical Investigation,

*reflection of disease severity in plasma cell dyscrasias.* The Journal of Clinical

Journal of Experimental Medicine, 1995. 182(1): p. 243-248.

British Journal of Haematology, 1996. 92(2): p. 370-374.

*factors in multiple myeloma.* Blood, 1995. 85(3): p. 765-771.

*myeloma.* Cancer, 1998. 82(10): p. 1860-1866.

Investigation, 1989. 84(6): p. 2008-2011.

*factors.* Blood, 1989. 73(7): p. 1915-1924.

*myelomas.* Nature, 1988. 332(6159): p. 83-84.

*multiple myeloma.* Blood, 1991. 77(12): p. 2688-2693.

*differentiation by interleukin-6.* Blood, 1989. 73(2): p. 517-526.

*with multiple myeloma.* Blood, 1989. 74(4): p. 1266-1273.

*marrow stromal cells.* Blood, 2003. 102(7): p. 2581-2592.

*cells.* Oncogene, 1999. 18(48): p. 6733-6740.


[5] Balkwill, F. and A. Mantovani, *Inflammation and cancer: Back to Virchow?* Lancet, 2001.

[6] Mantovani, A., *Molecular pathways linking inflammation and cancer.* Current Molecular

[7] Porta, C., et al., *Cellular and molecular pathways linking inflammation and cancer.*

[11] Katz, B.Z., *Adhesion molecules-The lifelines of multiple myeloma cells.* Seminars in Cancer

[12] Bewick, M.A. and R.M. Lafrenie, *Adhesion dependent signalling in the tumour* 

[13] Demchenko, Y.N., et al., *Classical and/or alternative NF-κB pathway activation in multiple* 

[14] Kawauchi, K., et al., *The PI3K/Akt pathway as a target in the treatment of hematologic malignancies.* Anti-Cancer Agents in Medicinal Chemistry, 2009. 9(5): p. 550-559. [15] Chim, C.S., et al., *SOCS1 and SHP1 hypermethylation in multiple myeloma: Implications for epigenetic activation of the Jak/STAT pathway.* Blood, 2004. 103(12): p. 4630-4635. [16] Hirano, T., T. Taga, and N. Nakano, *Purification to homogeneity and characterization of* 

*expression in tumor cells and bone marrow environment using Affymetrix microarrays.*

*microenvironment: The future of drug targeting.* Current Pharmaceutical Design, 2006.

*human B-cell differentiation factor (BCDF or BSFp-2).* Proceedings of the National Academy of Sciences of the United States of America, 1985. 82(16): p. 5490-5494. [17] Van Damme, J., G. Opdenakker, and R.J. Simpson, *Identification of the human 26-kD* 

*protein, interferon β2 (IFN-β2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor.* Journal of Experimental Medicine, 1987.

*IL-6, in human fibroblasts by IL-1: Use of HGF activity in specific and sensitive biological assays for IL-1 and IL-6.* Developments in Biological Standardization, 1988. 69: p. 31-

*proliferation of human plasmacytoma cells via the common signal transducer, GP130.*

*differentiation and survival signals relayed through the IL-6 family of cytokine receptors.*

*diseases and paraneoplastic syndromes.* Expert Opinion on Therapeutic Targets, 2005.

[18] Aarden, L.A., *Hybridoma growth factor.* Annals of the New York Academy of Sciences,

[19] Van Damme, J. and J. Van Snick, *Induction of hybridoma growth factor (HGF) identical to* 

[20] Nishimoto, N., et al., *Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the* 

[21] Hirano, T., K. Ishihara, and M. Hibi, *Roles of STAT3 in mediating the cell growth,* 

[22] Nishimoto, N. and T. Kishimoto, *Interleukin 6: From bench to bedside.* Nature Clinical

[23] Barton, B.E., *Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative* 

Journal of Experimental Medicine, 1994. 179(4): p. 1343-1347.

Oncogene, 2000. 19(21): p. 2548-2556.

Practice Rheumatology, 2006. 2(11): p. 619-626.

[8] Mantovani, A., et al., *Cancer-related inflammation.* Nature, 2008. 454(7203): p. 436-444. [9] Balkwill, F. and A. Mantovani, *Cancer and inflammation: Implications for pharmacology and therapeutics.* Clinical Pharmacology and Therapeutics, 2010. 87(4): p. 401-406. [10] Mahtouk, K., et al., *Growth factors in multiple myeloma: A comprehensive analysis of their* 

357(9255): p. 539-545.

BMC Cancer, 2010. 10.

12(22): p. 2833-2848.

165(3): p. 914-919.

9(4): p. 737-752.

38.

1989. 557: p. 192-199.

Biology, 2010. 20(3): p. 186-195.

Medicine, 2010. 10(4): p. 369-373.

Immunobiology, 2009. 214(9-10): p. 761-777.

*myeloma.* Blood, 2010. 115(17): p. 3541-3552.


Targeted Inhibition of Multiple Proinflammatory

106(3): p. 1021-1030.

439-445.

6675-6682.

901.

Cancer Research, 2004. 10(6): p. 1901-1910.

Immunology, 1997. 159(1): p. 487-496.

*cell growth.* Blood, 2000. 96(8): p. 2856-2861.

Haematology, 2000. 111(2): p. 626-634.

*and solid tumors.* Cancer cell, 2004. 5(3): p. 221-230.

Signalling Pathways for the Prevention and Treatment of Multiple Myeloma 115

[63] Johrer, K., et al., *Transendothelial Migration of Myeloma Cells Is Increased by Tumor Necrosis* 

[64] Novak, A.J., et al., *Expression of BCMA, TACI, and BAFF-R in multiple myeloma: A* 

[65] Moreaux, J., et al., *The level of TACI gene expression in myeloma cells is associated with a* 

[66] Li, W., et al., *New targets of PS-341: BAFF and APRIL.* Medical Oncology, 2010. 27(2): p.

[67] Tai, Y.T., et al., *Role of B-cell-activating factor in adhesion and growth of human multiple* 

[68] Moreaux, J., et al., *BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.* Blood, 2004. 103(8): p. 3148-3157. [69] Quinn, J., et al., *APRIL promotes cell-cycle progression in primary multiple myeloma cells:* 

[70] Standal, T., et al., *Serum insulin-like growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor.* Blood, 2002. 100(12): p. 3925-3929. [71] Jelinek, D.F., T.E. Witzig, and B.K. Arendt, *A Role for Insulin-Like Growth Factor in the* 

[72] Ogawa, M., et al., *Cytokines prevent dexamethasone-induced apoptosis via the activation of* 

[74] Ge, N.-L. and S. Rudikoff, *Insulin-like growth factor I is a dual effector of multiple myeloma* 

[75] Mitsiades, C.S., et al., *Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase* 

[76] Georgii-Hemming, P., et al., *Insulin-like growth factor I is a growth and survival factor in* 

[77] Freund, G.G., et al., *Functional Insulin and Insulin-like Growth Factor-1 Receptors Are* 

*human multiple myeloma cell lines.* Blood, 1996. 88(6): p. 2250-2258.

*Lymphoblastoid Cell Lines.* Cancer Research, 1994. 54(12): p. 3179-3185. [78] Xu, F., et al., *Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors.* British Journal of Haematology, 1997. 97(2): p. 429-440. [79] Abroun, S., et al., *Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I that highly express IL-6 receptor α myeloma cells.* Blood, 2004. 103(6): p. 2291-2298. [80] Ferlin, M., et al., *Insulin-like growth factor induces the survival and proliferation of myeloma* 

*multiple myeloma cell line1.* Cancer Research, 2000. 60(15): p. 4262-4269. [73] Vanderkerken, K., et al., *Insulin-Like Growth Factor-1 Acts as a Chemoattractant Factor for* 

*5T2 Multiple Myeloma Cells.* Blood, 1999. 93(1): p. 235-241.

*mechanism for growth and survival.* Blood, 2004. 103(2): p. 689-694.

*Factor (TNF)-α via TNF Receptor 2 and Autocrine Up-Regulation of MCP-1.* Clinical

*signature of microenvironment dependence versus a plasmablastic signature.* Blood, 2005.

*myeloma cells in the bone marrow microenvironment.* Cancer research, 2006. 66(13): p.

*Influence of D-type cyclin group and translocation status.* Blood, 2011. 117(3): p. 890-

*Regulation of IL-6-Responsive Human Myeloma Cell Line Growth.* Journal of

*mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new* 

*activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies,* 

*Preferentially Expressed in Multiple Myeloma Cell Lines as Compared to B-*

*cells through an interleukin-6-independent transduction pathway.* British Journal of


[45] Chauhan, D., et al., *SHP2 mediates the protective effect of interleukin-6 against* 

[46] Hideshima, T., et al., *Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in* 

[47] Salem, M., et al., *Identification of predictors of disease status and progression in patients with* 

[48] Thavasu, P.W., et al., *Multiple myeloma: An immunoclinical study of disease and response to* 

[49] Trikha, M., et al., *Targeted Anti-Interleukin-6 Monoclonal Antibody Therapy for Cancer: A* 

[50] Chatterjee, M., et al., *Combined disruption of both the MEK/ERK and the IL-6R/STAT3* 

[51] Chatterjee, M., et al., *In the presence of bone marrow stromal cells human multiple myeloma* 

[52] Wiemann, B. and C.O. Starnes, *Coley's toxins, tumor necrosis factor and cancer research: A historical perspective.* Pharmacology and Therapeutics, 1994. 64(3): p. 529-564. [53] O'Malley, W.E., B. Achinstein, and M.J. Shear, *ACTION OF BACTERIAL* 

[54] Carswell, E.A., L.J. Old, and R.L. Kassel, *An endotoxin induced serum factor that causes* 

[55] Oettgen, H.F., et al., *Endotoxin-induced tumor necrosis factor.* Recent results in cancer

[56] Pennica, D., G.E. Nedwin, and J.S. Hayflick, *Human tumour necrosis factor: Precursor* 

[57] Lejeune, F.J., *Clinical use of TNF revisited: Improving penetration of anti-cancer agents by* 

[58] Balkwill, F., *TNF-α in promotion and progression of cancer.* Cancer and Metastasis Reviews,

[59] Moore, R.J., et al., *Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis.*

[60] Arnott, C.H., et al., *Expression of both TNF-α receptor subtypes is essential for optimal skin* 

[61] Knight, B., et al., *Impaired preneoplastic changes and liver tumor formation in tumor necrosis* 

[62] Hideshima, T., et al., *The role of tumor necrosis factors in the pathophysiology of human multiple myeloma: Therapeutic applications.* Oncogene, 2001. 20(33): p. 4519-4527.

*factor receptor type 1 knockout mice.* Journal of Experimental Medicine, 2000. 192(12):

*tumour development.* Oncogene, 2004. 23(10): p. 1902-1910.

*Review of the Rationale and Clinical Evidence.* Clinical Cancer Research, 2003. 9(13): p.

*pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone* 

*cells become independent of the IL-6/gp130/STAT3 pathway.* Blood, 2002. 100(9): p. 3311-

*POLYSACCHARIDE ON TUMORS. III. REPEATED RESPONSE OF.* Cancer

*necrosis of tumors.* Proceedings of the National Academy of Sciences of the United

research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,

*structure, expression and homology to lymphotoxin.* Nature, 1984. 312(5996): p. 724-729.

*increasing vascular permeability.* Journal of Clinical Investigation, 2002. 110(4): p. 433-

Chemistry, 2000. 275(36): p. 27845-27850.

4653-4665.

3318.

435.

research, 1963. 23: p. 890-895.

1980. 75: p. 207-212.

2006. 25(3): p. 409-416.

p. 1809-1818.

States of America, 1975. 72(9): p. 3666-3670.

Nature Medicine, 1999. 5(7): p. 828-831.

*multiple myeloma.* Oncogene, 2001. 20(42): p. 5991-6000.

*treatment.* Hematological Oncology, 1995. 13(2): p. 69-82.

*marrow stromal cells.* Blood, 2004. 104(12): p. 3712-3721.

*myeloma (MM).* Hematology, 2000. 5(1): p. 41-45.

*dexamethasone-induced apoptosis in multiple myeloma cells.* Journal of Biological


Targeted Inhibition of Multiple Proinflammatory

4062-4070.

1995. 21(4): p. 367-403.

1998. 7(6): p. 497-504.

1999. 66(6): p. 981-988.

Nature, 1999. 397(6719): p. 530-534.

*myeloma.* Bone, 2011. 48(1): p. 129-134.

Haematologica, 1997. 98(2): p. 116-118.

*conflict.* Blood reviews, 1999. 13(3): p. 151-162.

Nat Genet, 1997. 16(3): p. 260-264.

Signalling Pathways for the Prevention and Treatment of Multiple Myeloma 117

[97] Bisping, G., et al., *Paracrine interactions of basic fibroblast growth factor and interleukin-6 in* 

[98] Chesi, M., et al., *Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated* 

[99] Richelda, R., et al., *A Novel Chromosomal Translocation t(4; 14)(p16.3; q32) in Multiple* 

[100] Zhu, L., et al., *Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to* 

[101] Hadari, Y. and J. Schlessinger, *FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma.* The Journal of Clinical Investigation, 2009. 119(5): p. 1077-1079. [102] Eswarakumar, V.P., I. Lax, and J. Schlessinger, *Cellular signaling by fibroblast growth factor receptors.* Cytokine & Growth Factor Reviews, 2005. 16(2): p. 139-149. [103] Alexandrow, M.G. and H.L. Moses, *Transforming Growth Factor β and Cell Cycle* 

[104] Pepper, M.S., *Transforming growth factor-beta: Vasculogenesis, angiogenesis, and vessel wall* 

[105] Taipale, J., J. Saharinen, and J. Keski-Oja, *Extracellular Matrix-Associated Transforming* 

[107] Letterio, J.J. and A.B. Roberts, *Regulation of immune responses by TGF-beta.* Annual

[108] Maehara, Y., et al., *Role of Transforming Growth Factor-ß1 in Invasion and Metastasis in* 

[109] Picon, A., et al., *A subset of metastatic human colon cancers expresses elevated levels of* 

[110] Hojo, M., et al., *Cyclosporine induces cancer progression by a cell-autonomous mechanism.*

[111] Matsumoto, T. and M. Abe, *TGF-β-related mechanisms of bone destruction in multiple* 

[112] Kroning, H., et al., *Overproduction of IL-7, IL-10 and TGF-beta 1 in multiple myeloma.* Acta

[113] Urashima, M., et al., *Transforming growth factor-beta1: differential effects on multiple* 

[114] Cook, G., et al., *Transforming growth factor beta from multiple myeloma cells inhibits* 

[115] Cook, G. and J.D.M. Campbell, *Immune regulation in multiple myeloma: the host–tumour* 

[116] Takeuchi, K., et al., *TGF-β Inhibition Restores Terminal Osteoblast Differentiation to* 

*proliferation and IL-2 responsiveness in T lymphocytes.* Journal of Leukocyte Biology,

*myeloma versus normal B cells.* Blood, 1996. 87(5): p. 1928-1938.

*Suppress Myeloma Growth.* PLoS ONE, 2010. 5(3): p. e9870.

*transforming growth factor beta1.* Cancer Epidemiology Biomarkers & Prevention,

*Gastric Carcinoma.* Journal of Clinical Oncology, 1999. 17(2): p. 607.

*Growth Factor-[beta]: Role in Cancer Cell Growth and Invasion*, in *Advances in Cancer Research*, F.V.W. George and K. George, Editors. 1998, Academic Press. p. 87-134. [106] Norgaard, P., et al., *Transforming growth factor β and cancer.* Cancer treatment reviews,

*integrity.* Cytokine & Growth Factor Reviews, 1997. 8(1): p. 21-43.

*with increased expression and activating mutations of fibroblast growth factor receptor 3.*

*Myeloma Involves the Fibroblast Growth-Factor Receptor 3 Gene.* Blood, 1997. 90(10): p.

*apoptosis in multiple myeloma.* Molecular Cancer Therapeutics, 2005. 4(5): p. 787-798.

*multiple myeloma.* Blood, 2003. 101(7): p. 2775-2783.

*Regulation.* Cancer Research, 1995. 55(7): p. 1452-1457.

Review of Immunology, 1998. 16: p. 137-161.


[81] Tu, Y., A. Gardner, and A. Lichtenstein, *The Phosphatidylinositol 3-Kinase/AKT Kinase* 

[82] Qiang, Y.-W., E. Kopantzev, and S. Rudikoff, *Insulin-like growth factor–I signaling in* 

[83] Asosingh, K., et al., *In Vivo Induction of Insulin-like Growth Factor-I Receptor and CD44v6* 

[84] Tai, Y.T., et al., *Insulin-like growth factor-1 induces adhesion and migration in human multiple* 

[85] Ge, N.L. and S. Rudikoff, *Insulin-like growth factor I is a dual effector of multiple myeloma* 

[86] Akiyama, M., et al., *Cytokines modulate telomerase activity in a human multiple myeloma cell* 

[87] Podar, K., et al., *Essential role of caveolae in interleukin-6- and insulin-like growth factor I-*

[88] Fukuda, R., et al., *Insulin-like Growth Factor 1 Induces Hypoxia-inducible Factor 1-mediated* 

[89] Miele, C., et al., *Insulin and Insulin-like Growth Factor-I Induce Vascular Endothelial Growth* 

[90] Mitsiades, C.S., et al., *Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase* 

[91] Sucak, G.T., et al., *Prognostic value of bone marrow microvessel density and angiogenic* 

[92] Sezer, O., et al., *Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF),* 

[93] Vacca, A., et al., *Bone Marrow Neovascularization, Plasma Cell Angiogenic Potential, and* 

[94] Bertolini, F., et al., *Thalidomide in multiple myeloma, myelodysplastic syndromes and* 

[95] Neben, K., et al., *High Plasma Basic Fibroblast Growth Factor Concentration Is Associated* 

[96] Neben, K., et al., *Response to thalidomide in progressive multiple myeloma is not mediated by* 

*myeloma.* European Journal of Haematology, 2001. 66(2): p. 83-88.

*Proliferative Responses.* Cancer Research, 2000. 60(23): p. 6763-6770.

*signaling.* Cancer Research, 2003. 63(18): p. 5850-5858.

*cell growth.* Blood, 2000. 96(8): p. 2856-2861.

Chemistry, 2003. 278(8): p. 5794-5801.

Chemistry, 2002. 277(41): p. 38205-38211.

Chemistry, 2000. 275(28): p. 21695-21702.

Blood, 1999. 93(9): p. 3064-3073.

Oncology, 2001. 12(7): p. 987-990.

Research, 2001. 7(9): p. 2675-2681.

115(3): p. 605-608.

*and solid tumors.* Cancer cell, 2004. 5(3): p. 221-230.

Leukemia & Lymphoma, 2011. 52(7): p. 1281-1289.

*line.* Cancer Research, 2002. 62(13): p. 3876-3882.

Blood, 2002. 99(11): p. 4138-4146.

2000. 60(11): p. 3096-3104.

*Pathway in Multiple Myeloma Plasma Cells: Roles in Cytokine-dependent Survival and* 

*multiple myeloma: downstream elements, functional correlates, and pathway cross-talk.*

*Confers Homing and Adhesion to Murine Multiple Myeloma Cells.* Cancer Research,

*myeloma cells via activation of β1-integrin and phosphatidylinositol 3′-kinase/AKT* 

*triggered Akt-1-mediated survival of multiple myeloma cells.* Journal of Biological

*Vascular Endothelial Growth Factor Expression, Which is Dependent on MAP Kinase and Phosphatidylinositol 3-Kinase Signaling in Colon Cancer Cells.* Journal of Biological

*Factor mRNA Expression via Different Signaling Pathways.* Journal of Biological

*activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies,* 

*cytokines in patients with multiple myeloma undergoing autologous stem cell transplant.*

*vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple* 

*Matrix Metalloproteinase-2 Secretion Parallel Progression of Human Multiple Myeloma.*

*histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers.* Annals of

*with Response to Thalidomide in Progressive Multiple Myeloma.* Clinical Cancer

*inhibition of angiogenic cytokine secretion.* British Journal of Haematology, 2001.


Targeted Inhibition of Multiple Proinflammatory

Immunology, 1999. 29(12): p. 3945-3950.

Park, N.Y.), 2004. 18(13 Suppl 10): p. 21-24.

Gene Therapy, 2006. 13(2): p. 194-202.

Haematology, 2000. 109(4): p. 823-828.

Journal of Immunology, 2003. 171(7): p. 3863-3871.

820.

377-383.

80.

British Journal of Haematology, 1999. 107(2): p. 392-395.

Signalling Pathways for the Prevention and Treatment of Multiple Myeloma 119

[134] Puthier, D., R. Bataille, and M. Amiot, *IL-6 up-regulates Mcl-1 in human myeloma cells* 

[135] Puthier, D., et al., *Mcl-1 and Bcl-X(L) are co-regulated by IL-6 in human myeloma cells.*

[136] Spets, H., et al., *Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple* 

[139] Chanan-Khan, A.A., *Bcl-2 antisense therapy in multiple myeloma.* Oncology (Williston

[140] Quintanilla-Martinez, L., et al., *Analysis of signal transducer and activator of transcription 3* 

[141] Galm, O., et al., *SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by* 

[142] Yamamoto, M., et al., *Suppressor of cytokine signaling-1 expression by infectivity-enhanced* 

[143] Amit-Vazina, M., et al., *Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells.* British Journal of Cancer, 2005. 93(1): p. 70-80. [144] Bai, L.Y., et al., *OSU-03012 sensitizes TIB-196 myeloma cells to imatinib mesylate via AMP-*

[145] Bharti, A.C., N. Donato, and B.B. Aggarwal, *Curcumin (diferuloylmethane) inhibits* 

[146] Bhutani, M., et al., *Capsaicin is a novel blocker of constitutive and interleukin-6 - Inducible STAT3 activation.* Clinical Cancer Research, 2007. 13(10): p. 3024-3032. [147] Che, Y., et al., *Serenoa repens induces growth arrest and apoptosis of human multiple* 

[148] De Vos, J., et al., *JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the* 

[149] Heo, J.Y., et al., *Embelin suppresses STAT3 signaling, proliferation, and survival of multiple* 

[150] Kim, H.J., et al., *Decursin chemosensitizes human multiple myeloma cells through inhibition* 

[151] Kim, S.H., et al., *Janus activated kinase 2/signal transducer and activator of transcription 3* 

*of STAT3 signaling pathway.* Cancer Letters, 2011. 301(1): p. 29-37.

European Journal of Pharmacology, 2011. 654(1): p. 10-16.

*(Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events.* American Journal of Pathology, 2003. 162(5): p. 1449-1461.

*adenoviral vector inhibits IL-6-dependent proliferation of multiple myeloma cells.* Cancer

*activated protein kinase and STAT3 pathways.* Leukemia Research, 2010. 34(6): p. 816-

*constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells.*

*myeloma cells via inactivation of STAT 3 signaling.* Oncology Reports, 2009. 22(2): p.

*mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells.* British Journal of

*myeloma via the protein tyrosine phosphatase PTEN.* Cancer Letters, 2011. 308(1): p. 71-

*pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells.*

*and survival.* European Journal of Haematology, 2002. 69(2): p. 76-89. [137] Catlett-Falcone, R., et al., *Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells.* Immunity, 1999. 10(1): p. 105-115. [138] Song, L., et al., *Mcl-1 mediates cytokine deprivation induced apoptosis of human myeloma cell* 

*line XG-7.* Chinese Medical Journal, 2002. 115(8): p. 1241-1243.

*methylation in multiple myeloma.* Blood, 2003. 101(7): p. 2784-2788.

*through JAK/STAT rather than Ras/MAP kinase pathway.* European Journal of

*myeloma and normal plasma cells: Regulation during interleukin-6 (IL-6)-induced growth* 


[117] Choi, S.J., et al., *Antisense inhibition of macrophage inflammatory protein 1-α blocks bone* 

[118] Lentzsch, S., et al., *Macrophage inflammatory protein 1-alpha (MIP-1α) triggers migration* 

[119] Menu, E., et al., *Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in* 

[120] Vanderkerken, K., et al., *Monocyte chemoattractant protein-1 (MCP-1), secreted by bone* 

[121] Vande Broek, I., et al., *Chemokine receptor CCR2 is expressed by human multiple myeloma* 

*proteins MCP-1, -2 and -3.* British Journal of Cancer, 2003. 88(6): p. 855-862. [122] Pellegrino, A., et al., *CXCR3-binding chemokines in multiple myeloma.* Cancer Letters,

[123] Pellegrino, A., et al., *Bone marrow endothelial cells in multiple myeloma secrete CXC-*

[124] Hideshima, T., et al., *The biological sequelae of stromal cell-derived factor-1alpha in multiple* 

[125] Menu, E., et al., *The involvement of stromal derived factor 1α in homing and progression of multiple myeloma in the 5TMM model.* Haematologica, 2006. 91(5): p. 605-612. [126] Gazitt, Y. and C. Akay, *Mobilization of Myeloma Cells Involves SDF-1/CXCR4 Signaling* 

[127] Alsayed, Y., et al., *Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.* Blood, 2007. 109(7): p. 2708-2717. [128] Darnell Jr, J.E., I.M. Kerr, and G.R. Stark, *Jak-STAT pathways and transcriptional* 

[129] Akira, S., et al., *Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related* 

[130] Bromberg, J., *Stat proteins and oncogenesis.* Journal of Clinical Investigation, 2002. 109(9):

[131] Alvarez, J.V. and D.A. Frank, *Genome-wide analysis of STAT target genes: Elucidating the* 

[132] Takeda, K., et al., *Targeted disruption of the mouse Stat3 gene leads to early embryonic* 

[133] Akira, S., *Roles of STAT3 defined by tissue-specific gene targeting.* Oncogene, 2000. 19(21):

*activation in response to IFNs and other extracellular signaling proteins.* Science, 1994.

*transcription factor involved in the gp130-mediated signaling pathway.* Cell, 1994. 77(1):

*mechanism of STAT-mediated oncogenesis.* Cancer Biology and Therapy, 2004. 3(11): p.

*lethality.* Proceedings of the National Academy of Sciences of the United States of

*myeloma.* Molecular cancer therapeutics, 2002. 1(7): p. 539-544.

*and Downregulation of VLA-4.* Stem Cells, 2004. 22(1): p. 65-73.

108(12): p. 1833-1841.

2004. 207(2): p. 221-227.

2005. 129(2): p. 248-256.

264(5164): p. 1415-1421.

America, 1997. 94(8): p. 3801-3804.

p. 63-71.

p. 1139-1142.

1045-1050.

p. 2607-2611.

*cells.* Blood, 2003. 101(9): p. 3568-3573.

Experimental Metastasis, 2006. 23(5-6): p. 291-300.

and Experimental Metastasis, 2002. 19(1): p. 87-90.

*destruction in a model of myeloma bone disease.* Journal of Clinical Investigation, 2001.

*and signaling cascades mediating survival and proliferation in multiple myeloma (MM)* 

*the development of osteolytic lesions: A study in the 5TMM model.* Clinical and

*marrow endothelial cells, induces chemoattraction of 5T multiple myeloma cells.* Clinical

*cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic* 

*chemokines that mediate interactions with plasma cells.* British Journal of Haematology,


Targeted Inhibition of Multiple Proinflammatory

Research, 2007. 5(9): p. 943-955.

Reports, 2011. 4(2): p. 313-318.

25(3): p. 538-550.

12(2): p. 115-130.

Signalling Pathways for the Prevention and Treatment of Multiple Myeloma 121

[168] Pathak, A.K., et al., *Ursolic acid inhibits STAT3 activation pathway leading to suppression of* 

[169] Pedranzini, L., et al., *Pyridone 6, a Pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells.* Cancer research, 2006. 66(19): p. 9714-9721. [170] Peng, J., et al., *Patrinia scabiosaefolia extract suppresses proliferation and promotes apoptosis* 

[171] Ramakrishnan, V., et al., *TG101209, a novel JAK2 inhibitor, has significant in vitro activity* 

[172] Sagawa, M., et al., *Cantharidin induces apoptosis of human multiple myeloma cells via inhibition of the JAK/STAT pathway.* Cancer Science, 2008. 99(9): p. 1820-1826. [173] Santo, L., et al., *Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent* 

[174] Scuto, A., et al., *The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling,* 

[175] Zhang, S., et al., *The novel histone deacetylase inhibitor, AR-42, inhibits gp130/Stat3 pathway* 

[176] Sethi, G., B. Sung, and B.B. Aggarwal, *Nuclear factor-κB activation: From bench to bedside.*

[177] Sethi, G. and V. Tergaonkar, *Potential pharmacological control of the NF-κB pathway.*

[178] Weaver, D. and D. Baltimore, *B lymphocyte-specific protein binding near an* 

[179] Aggarwal, B.B., *Nuclear factor-κB: The enemy within.* Cancer Cell, 2004. 6(3): p. 203-208. [180] Pikarsky, E., et al., *NF-κB functions as a tumour promoter in inflammation-associated cancer.*

[181] Greten, F.R., et al., *IKKβ links inflammation and tumorigenesis in a mouse model of colitis-*

[182] Seitz, C.S., et al., *Alterations in NF-κB function in transgenic epithelial tissue demonstrate a* 

[183] Bharti, A.C., et al., *Nuclear factor-κB and STAT3 are constitutively active in CD138 + cells* 

[184] Keats, J.J., et al., *Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in* 

[185] Annunziata, C.M., et al., *Frequent Engagement of the Classical and Alternative NF-κB* 

*growth inhibitory role for NF-κB.* Proceedings of the National Academy of Sciences of

*derived from multiple myeloma patients, and suppression of these transcription factors leads* 

*Pathways by Diverse Genetic Abnormalities in Multiple Myeloma.* Cancer Cell, 2007.

American Journal of Hematology, 2010. 85(9): p. 675-686.

Clinical Cancer Research, 2011. 17(10): p. 3259-3271.

Experimental Biology and Medicine, 2008. 233(1): p. 21-31.

Trends in Pharmacological Sciences, 2009. 30(6): p. 313-321.

the United States of America, 1987. 84(6): p. 1516-1520.

the United States of America, 1998. 95(5): p. 2307-2312.

*Multiple Myeloma.* Cancer Cell, 2007. 12(2): p. 131-144.

Journal of Cancer, 2011. 129(1): p. 204-213.

Nature, 2004. 431(7007): p. 461-466.

*associated cancer.* Cell, 2004. 118(3): p. 285-296.

*to apoptosis.* Blood, 2004. 103(8): p. 3175-3184.

*proliferation and chemosensitization of human multiple myeloma cells.* Molecular Cancer

*by inhibiting the STAT3 pathway in human multiple myeloma cells.* Molecular Medicine

*in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells.*

*Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.*

*resulting in suppression of human myeloma cell growth and survival.* Leukemia, 2011.

*and induces apoptosis and cell cycle arrest in multiple myeloma cells.* International

*immunoglobulin κ-chain gene J segment (DNA binding protein/B cell-specific protein/DNA rearranggement).* Proceedings of the National Academy of Sciences of


[152] Kim, S.H., et al., *Signal transducer and activator of transcription 3 pathway mediates genipin-*

[153] Kunnumakkara, A.B., et al., *Boswellic acid blocks signal transducers and activators of* 

[155] Li, J., et al., *INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma* 

[156] Lin, L., et al., *A novel small molecule inhibits STAT3 phosphorylation and DNA binding* 

[157] Liu, S., et al., *Inhibitory effect of baicalein on IL-6-mediated signaling cascades in human myeloma cells.* European Journal of Haematology, 2010. 84(2): p. 137-144. [158] Ma, J., et al., *Therapeutic potential of cladribine in combination with STAT3 inhibitor against* 

[159] Ma, J., et al., *Mechanism of MS-275 blocking STAT3 and NF-κB signaling, inducing* 

[160] Malara, N., et al., *Simultaneous inhibition of the constitutively activated nuclear factor κB* 

[161] Muto, A., et al., *Emodin has a cytotoxic activity against human multiple myeloma as a Janusactivated kinase 2 inhibitor.* Molecular cancer therapeutics, 2007. 6(3): p. 987-994. [162] Nakaya, A., et al., *The gold compound auranofin induces apoptosis of human multiple* 

[163] Nelson, E.A., et al., *Nifuroxazide inhibits survival of multiple myeloma cells by directly* 

[164] Pandey, M.K., et al., *Butein suppresses constitutive and inducible signal transducer and* 

[165] Pandey, M.K., B. Sung, and B.B. Aggarwal, *Betulinic acid suppresses STAT3 activation* 

[167] Park, S., et al., *Inhibition of JAK1/STAT3 signaling mediates compound K-induced apoptosis* 

*myeloma cells.* International Journal of Cancer, 2010. 127(2): p. 282-292. [166] Park, J., et al., *Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically* 

2011. 112(6): p. 1552-1562.

2010. 12(1): p. 28-38.

16(16): p. 1234-1237.

75(3): p. 525-533.

2008. 19(8): p. 777-782.

1367-1372.

Cancer, 2010. 9.

Pharmacology, 2010. 161(3): p. 541-554.

*multiple myeloma.* BMC Cancer, 2011: p. 255.

Leukemia Research, 2011. 35(2): p. 243-249.

*inhibiting STAT3.* Blood, 2008. 112(13): p. 5095-5102.

*induced apoptosis in U266 multiple myeloma cells.* Journal of Cellular Biochemistry,

*transcription 3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1.* Molecular Cancer Research, 2009. 7(1): p. 118-128. [154] Li, F., P. Rajendran, and G. Sethi, *Thymoquinone inhibits proliferation, induces apoptosis* 

*and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway.* British Journal of

*cells and reverses the protective effects of cytokine and stromal cell support.* Neoplasia,

*activity and exhibits potent growth suppressive activity in human cancer cells.* Molecular

*apoptosis in U266 cells.* Chinese Journal of Cancer Prevention and Treatment, 2009.

*and of the Interleukin-6 pathways is necessary and sufficient to completely overcome apoptosis resistance of human U266 myeloma cells.* Cell Cycle, 2008. 7(20): p. 3235-3245.

*myeloma cells through both down-regulation of STAT3 and inhibition of NF-κB activity.*

*activator of transcription (stat) 3 activation and stat3-regulated gene products through the induction of a protein tyrosine phosphatase SHP-1.* Molecular Pharmacology, 2009.

*pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple* 

*induces the inhibitory effect of bortezomib in human U266 cells.* Anti-Cancer Drugs,

*in human multiple myeloma U266 cells.* Food and Chemical Toxicology, 2011. 49(6): p.


Targeted Inhibition of Multiple Proinflammatory

551-559.

Journal of Haematology, 1994. 87(3): p. 503-508.

Clinical Cancer Research, 2000. 6(8): p. 3111-3116.

Hematology, 2001. 80(10): p. 598-601.

Oncology, 2001. 19(2): p. 577-583.

Blood, 2003. 102(4): p. 1435-1442.

Blood, 1998. 92(8): p. 2908-2913.

Chemistry, 2003. 278(49): p. 48745-48753.

Medicine, 1996. 2(11): p. 1267-1267.

17(10): p. 2025-2031.

p. 161-164.

*Studies.* Leukemia & Lymphoma, 1995. 20(1-2): p. 27-38.

Signalling Pathways for the Prevention and Treatment of Multiple Myeloma 123

[206] Vacca, A., et al., *Bone marrow angiogenesis and progression in multiple myeloma.* British

[207] Vacca, A., et al., *Angiogenesis in B Cell Lymphoproliferative Diseases. Biological and Clinical* 

[208] Rajkumar, S.V., et al., *Prognostic Value of Bone Marrow Angiogenesis in Multiple Myeloma.*

[209] Sezer, et al., *Relationship between bone marrow angiogenesis and plasma cell infiltration and* 

[210] Di Raimondo, F., et al., *Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.* Haematologica, 2000. 85(8): p. 800-805. [211] Ribatti, D., et al., *Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma.* Br J Cancer, 1999. 79(3-4): p. 451-455. [212] Bellamy, W.T., *Expression of vascular endothelial growth factor and its receptors in multiple* 

[213] Ugurel, S., et al., *Increased Serum Concentration of Angiogenic Factors in Malignant* 

[214] Iwasaki, T. and H. Sano, *Predicting Treatment Responses and Disease Progression in* 

[215] Hayashi, T., et al., *Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes.*

[216] Hideshima, T., et al., *Novel therapies targeting the myeloma cell and its bone marrow* 

[217] Podar, K., et al., *Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.* Blood, 2001. 98(2): p. 428-435. [218] Bellamy, W.T., et al., *Expression of Vascular Endothelial Growth Factor and Its Receptors in* 

[219] Kumar, S., et al., *Expression of VEGF and its receptors by myeloma cells.* Leukemia, 0000.

[220] Yaccoby, S., B. Barlogie, and J. Epstein, *Primary Myeloma Cells Growing in SCID-hu Mice:* 

[221] Hideshima, T., et al., *Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.* Nature Reviews Cancer, 2007. 7(8): p. 585-598. [222] Nakagawa, M., et al., *Vascular endothelial growth factor (VEGF) directly enhances* 

[223] Henriksen, K., et al., *RANKL and Vascular Endothelial Growth Factor (VEGF) Induce* 

[224] Gabrilovich, D.I., et al., *Production of vascular endothelial growth factor by human tumors* 

*A Model for Studying the Biology and Treatment of Myeloma and Its Manifestations.*

*osteoclastic bone resorption and survival of mature osteoclasts.* Febs Letters, 2000. 473(2):

*Osteoclast Chemotaxis through an ERK1/2-dependent Mechanism.* Journal of Biological

*inhibits the functional maturation of dendritic cells (vol 2, pg 1096, 1996).* Nature

*Levels.* Leukemia & Lymphoma, 2003. 44(8): p. 1347-1351.

*microenvironment.* Seminars in oncology, 2001. 28(6): p. 607-612.

*Hematopoietic Malignancies.* Cancer Research, 1999. 59(3): p. 728-733.

*serum ß2-microglobulin levels in patients with multiple myeloma.* Annals of

*myeloma and other hematopoietic malignancies.* Seminars in oncology, 2001. 28(6): p.

*Melanoma Patients Correlates With Tumor Progression and Survival.* Journal of Clinical

*Myeloma using Serum Vascular Endothelial Growth Factor and Hepatocyte Growth Factor* 


[186] Berenson, J.R., H.M. Ma, and R. Vescio, *The role of nuclear factor-κB in the biology and treatment of multiple myeloma.* Seminars in Oncology, 2001. 28(6): p. 626-633. [187] Feinman, R., et al., *Role of NF-κB in the rescue of multiple myeloma cells from glucocorticoid-*

[188] Hideshima, T., et al., *NF-κB as a therapeutic target in multiple myeloma.* Journal of

[189] Brinckerhoff, C.E. and L.M. Matrisian, *Matrix metalloproteinases: A tail of a frog that became a prince.* Nature Reviews Molecular Cell Biology, 2002. 3(3): p. 207-214. [190] Egeblad, M. and Z. Werb, *New functions for the matrix metalloproteinases in cancer* 

[191] Zdzisińska, B., et al., *Matrix metalloproteinase and cytokine production by bone marrow* 

[192] Vande Broek, I., et al., *Bone marrow endothelial cells increase the invasiveness of human* 

[193] Van Valckenborgh, E., et al., *Multifunctional role of matrix metalloproteinases in multiple* 

[194] Klagsbrun, M. and P. A. D'Amore, *Vascular endothelial growth factor and its receptors.*

[195] Dvorak, H.F., *Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical* 

[196] Asahara, T., et al., *Synergistic Effect of Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor on Angiogenesis In Vivo.* Circulation, 1995. 92(9): p. 365-371. [197] Aguayo, A., et al., *Angiogenesis in acute and chronic leukemias and myelodysplastic* 

[198] Salven, P., et al., *Simultaneous elevation in the serum concentrations of the angiogenic growth* 

[200] Aguayo, A., et al., *Clinical relevance of intracellular vascular endothelial growth factor levels* 

[201] *A Predictive Model for Aggressive Non-Hodgkin's Lymphoma.* New England Journal of

[202] Inoue, M., et al., *VEGF-A has a critical, nonredundant role in angiogenic switching and* 

[203] Moehler, T.M., et al., *Angiogenesis in hematologic malignancies.* Critical reviews in

[204] Rajkumar, S.V. and R.A. Kyle, *Angiogenesis in multiple myeloma.* Seminars in oncology,

[205] Jakob, C., et al., *Angiogenesis in multiple myeloma.* European journal of cancer (Oxford,

*in B-cell chronic lymphocytic leukemia.* Blood, 2000. 96(2): p. 768-770.

*pancreatic ² cell carcinogenesis.* Cancer cell, 2002. 1(2): p. 193-202.

*adherent cells from multiple myeloma patients.* Archivum Immunologiae et Therapiae

*multiple myeloma cells through upregulation of MMP-9: Evidence for a role of hepatocyte* 

*myeloma: A study in the 5T2MM mouse model.* American Journal of Pathology, 2004.

*Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy.*

*factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients.* Blood, 2000. 96(12): p. 3712-3718. [199] Molica, S., et al., *Increased serum levels of vascular endothelial growth factor predict risk of* 

*progression in early B-cell chronic lymphocytic leukaemia.* British Journal of

*induced apoptosis by bcl-2.* Blood, 1999. 93(9): p. 3044-3052.

*progression.* Nature Reviews Cancer, 2002. 2(3): p. 161-174.

Cytokine & Growth Factor Reviews, 1996. 7(3): p. 259-270.

Journal of Clinical Oncology, 2002. 20(21): p. 4368-4380.

*syndromes.* Blood, 2000. 96(6): p. 2240-2245.

Haematology, 1999. 107(3): p. 605-610.

Medicine, 1993. 329(14): p. 987-994.

2001. 28(6): p. 560-564.

oncology/hematology, 2003. 45(3): p. 227-244.

England : 1990), 2006. 42(11): p. 1581-1590.

Biological Chemistry, 2002. 277(19): p. 16639-16647.

Experimentalis, 2006. 54(4): p. 289-296.

165(3): p. 869-878.

*growth factor.* Leukemia, 2004. 18(5): p. 976-982.


Targeted Inhibition of Multiple Proinflammatory

60(8): p. 2178-2189.

and Lymphoma, 2001. 41(3-4): p. 239-245.

*and VCAM-1.* Blood, 2001. 97(2): p. 346-351.

Cancer research, 2009. 69(3): p. 1009-1015.

22(52): p. 8386-8393.

Blood, 1992. 80(9): p. 2306-2314.

Signalling Pathways for the Prevention and Treatment of Multiple Myeloma 125

[240] Waltenberger, J., et al., *DIFFERENT SIGNAL-TRANSDUCTION PROPERTIES OF KDR* 

[241] Le Gouill, S., et al., *VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells* 

[242] Meyer, R.D., et al., *The presence of a single tyrosine residue at the carboxyl domain of vascular* 

[243] Rousseau, S., et al., *Vascular Endothelial Growth Factor (VEGF)-driven Actin-based Motility* 

[245] Ferrara, N., et al., *Discovery and development of bevacizumab, an anti-VEGF antibody for* 

[246] Lin, B., et al., *The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor* 

[248] Sloan, B. and N.S. Scheinfeld, *Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy.* Current Opinion in Investigational Drugs, 2008. 9(12): p. 1324-1335.

[251] Sanz-Rodríguez, F., et al., *Characterization of VLA-4-dependent myeloma cell adhesion to fibronectin and VCAM-1.* British Journal of Haematology, 1999. 107(4): p. 825-834. [252] Uchiyama, H., et al., *Characterization of adhesion molecules on human myeloma cell lines.*

[253] Sanz-Rodríguez, F., A. Hidalgo, and J. Teixidó, *Chemokine stromal cell-derived factor-1α*

[254] Damiano, J.S., et al., *Cell adhesion mediated drug resistance (CAM-DR): Role of integrins* 

[255] Landowski, T.H., et al., *Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells.* Oncogene, 2003. 22(16): p. 2417-2421. [256] Shain, K.H., et al., *β1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma* 

[257] Fulciniti, M., et al., *A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma.* Clinical Cancer Research, 2009. 15(23): p. 7144-7152. [258] Hideshima, T., et al., *Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades* 

*modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin* 

*and resistance to apoptosis in human myeloma cell lines.* Blood, 1999. 93(5): p. 1658-1667.

*cells: Implications for microenvironment influence on tumor survival and proliferation.*

*via caspase-dependent downregulation of gp130 in multiple myeloma.* Oncogene, 2003.

[249] Thiery, J.P., *Cell adhesion in cancer.* Comptes Rendus Physique, 2003. 4(2): p. 289-304. [250] Sanz-Rodríguez, F. and J. Teixidó, *VLA-4-dependent myeloma cell adhesion.* Leukemia

*Marrow Microenvironment.* Cancer Research, 2002. 62(17): p. 5019-5026. [247] Wood, J.M., et al., *PTK787/ZK 222584, a Novel and Potent Inhibitor of Vascular Endothelial* 

*Kinase.* Journal of Biological Chemistry, 2000. 275(14): p. 10661-10672. [244] Kim, K.J., et al., *Inhibition of vascular endothelial growth factor-induced angiogenesis* 

*suppresses tumour growth in vivo.* Nature, 1993. 362(6423): p. 841-844.

*treating cancer.* Nat Rev Drug Discov, 2004. 3(5): p. 391-400.

Journal of Biological Chemistry, 1994. 269(43): p. 26988-26995.

*against apoptosis.* Blood, 2004. 104(9): p. 2886-2892.

*AND FLT1, 2 RECEPTORS FOR VASCULAR ENDOTHELIAL GROWTH-FACTOR.*

*endothelial growth factor receptor-2/FLK-1 regulates its autophosphorylation and activation of signaling molecules.* Journal of Biological Chemistry, 2002. 277(30): p. 27081-27087.

*Is Mediated by VEGFR2 and Requires Concerted Activation of Stress-activated Protein Kinase 2 (SAPK2/p38) and Geldanamycin-sensitive Phosphorylation of Focal Adhesion* 

*PTK787/ZK222584 Inhibits Growth and Migration of Multiple Myeloma Cells in the Bone* 

*Growth Factor Receptor Tyrosine Kinases, Impairs Vascular Endothelial Growth Factorinduced Responses and Tumor Growth after Oral Administration.* Cancer Research, 2000.


[225] Dankbar, B., et al., *Vascular endothelial growth factor and interleukin-6 in paracrine tumorstromal cell interactions in multiple myeloma.* Blood, 2000. 95(8): p. 2630-2636. [226] Neufeld, G., et al., *Vascular endothelial growth factor (VEGF) and its receptors.* The FASEB

[227] Li, J., et al., *Induction of Vascular Endothelial Growth Factor Gene Expression by Interleukin-*

[228] Matsumoto, K., H. Ohi, and K. Kanmatsuse, *Interleukin 10 and interleukin 13 synergize to* 

[229] Gupta, D., et al., *Adherence of multiple myeloma cells to bone marrow stromal cells* 

[230] Goad, D.L., et al., *Enhanced expression of vascular endothelial growth factor in human SaOS-*

[231] Deroanne, C.F., et al., *Angiogenesis by Fibroblast Growth Factor 4 Is Mediated through an* 

[232] Finkenzeller, G., et al., *Sp1 recognition sites in the proximal promoter of the human vascular* 

[233] Pertovaara, L., et al., *Vascular endothelial growth factor is induced in response to* 

[234] Ryuto, M., et al., *Induction of Vascular Endothelial Growth Factor by Tumor Necrosis Factor* 

[235] Wang, T.-H., et al., *Human Chorionic Gonadotropin-Induced Ovarian Hyperstimulation* 

Journal of Clinical Endocrinology & Metabolism, 2002. 87(7): p. 3300-3308. [236] Hurt, E.M., et al., *Overexpression of c-maf is a frequent oncogenic event in multiple myeloma* 

[237] Gerber, H.P., et al., *Vascular endothelial growth factor regulates endothelial cell survival* 

[238] Podar, K., et al., *Vascular Endothelial Growth Factor-induced Migration of Multiple* 

[239] Qi, J.H. and L. Claesson-Welsh, *VEGF-induced activation of phosphoinositide 3-kinase is* 

*patients with lipoid nephrosis.* Nephron, 1997. 77(2): p. 212-218.

*1 in Rat Aortic Smooth Muscle Cells.* Journal of Biological Chemistry, 1995. 270(1): p.

*inhibit vascular permeability factor release by peripheral blood mononuclear cells from* 

*upregulates vascular endothelial growth factor secretion: therapeutic applications.*

*2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I.*

*Autocrine Up-Regulation of Vascular Endothelial Growth Factor Expression.* Cancer

*endothelial growth factor gene are essential for platelet-derived growth factor-induced gene* 

*transforming growth factor-beta in fibroblastic and epithelial cells.* Journal of Biological

*α in Human Glioma Cells.* Journal of Biological Chemistry, 1996. 271(45): p. 28220-

*Syndrome Is Associated with Up-Regulation of Vascular Endothelial Growth Factor.*

*that promotes proliferation and pathological interactions with bone marrow stroma.* Cancer

*through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway: Requirement for Flk-1/KDR activation.* Journal of Biological Chemistry, 1998. 273(46): p. 30336-

*Myeloma Cells Is Associated with β1 Integrin- and Phosphatidylinositol 3-Kinasedependent PKCα Activation.* Journal of Biological Chemistry, 2002. 277(10): p. 7875-

*dependent on focal adhesion kinase.* Experimental Cell Research, 2001. 263(1): p. 173-

Journal, 1999. 13(1): p. 9-22.

Leukemia, 2001. 15(12): p. 1950-1961.

Endocrinology, 1996. 137(6): p. 2262-8.

Research, 1997. 57(24): p. 5590-5597.

Chemistry, 1994. 269(9): p. 6271-6274.

cell, 2004. 5(2): p. 191-199.

*expression.* Oncogene, 1997. 15(6): p. 669-76.

308-312.

28228.

30343.

7881.

182.


Targeted Inhibition of Multiple Proinflammatory

1995. 9(13): p. 1336-1344.

Discovery, 2009. 4: p. 54-72.

Blood, 2009. 113(18): p. 4341-4351.

*Cells.* Br J Pharmacol, 2011.

2007. 109(6): p. 2293-2302.

103(7): p. 2761-2770.

26-35.

107-118.

*vitro and in vivo.* Blood, 2005. 105(11): p. 4470-4476.

*myeloma.* Haematologica, 2008. 93(6): p. 860-869.

Signalling Pathways for the Prevention and Treatment of Multiple Myeloma 127

[275] Hayry, P., et al., *Stabile D-peptide analog of insulin-like growth factor-1 inhibits smooth* 

[276] Pietrzkowski, Z., et al., *Inhibition of Growth of Prostatic Cancer Cell Lines by Peptide Analogues of Insulin-like Growth Factor 1.* Cancer Research, 1993. 53(5): p. 1102-1106. [277] *Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel* 

[278] Hayashi, T., et al., *Transforming growth factor β receptor I kinase inhibitor down-regulates* 

[281] Oliveira, A.M., et al., *Thalidomide treatment down-regulates SDF-1α and CXCR4 expression in multiple myeloma patients.* Leukemia Research, 2009. 33(7): p. 970-973. [282] Haridas, V., et al., *Avicin D: A protein reactive plant isoprenoid dephosphorylates Stat3 by regulating both kinase and phosphatase activities.* PLoS ONE, 2009. 4(5). [283] Hamasaki, M., et al., *Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-*

[284] Kannaiyan, R., et al., *Celastrol Inhibits Proliferation and Induces Chemosensitization through* 

[285] Burger, R., et al., *Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on* 

[286] Sandur, S.K., et al., *5-Hydroxy-2-methyl-1,4-naphthoquinone, a vitamin K3 analogue,* 

[287] Bhardwaj, A., et al., *Resveratrol inhibits proliferation, induces apoptosis, and overcomes* 

[288] Khong, T., J. Sharkey, and A. Spencer, *The effect of azacitidine on interleukin-6 signaling* 

[289] Dai, Y., et al., *Interruption of the NF-κB pathway by Bay 11-7082 promotes UCN-01-mediated* 

*microenvironment.* Clinical Cancer Research, 2004. 10(22): p. 7540-7546. [279] Beider, K., et al., *CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth.* Experimental Hematology, 2011. 39(3): p. 282-292. [280] Azab, A.K., et al., *CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma* 

National Academy of Sciences, 1986. 83(3): p. 664-668.

*mitogenic mechanisms of IGF-I and insulin in human skin fibroblasts.* Proceedings of the

*muscle cell proliferation after carotid ballooning injury in the rat.* The FASEB Journal,

*Treatment Strategies for Cancer Medicine.* Recent Patents on Anti-Cancer Drug

*cytokine secretion and multiple myeloma cell growth in the bone marrow* 

*cells with the bone marrow microenvironment and enhances their sensitivity to therapy.*

*propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in* 

*downregulation of NF-kappaB and STAT3 Regulated Gene Products in Multiple Myeloma* 

*human myeloma cells in vitro and in vivo.* Molecular cancer therapeutics, 2009. 8(1): p.

*suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase, SHP-1: Potential role in chemosensitization.* Molecular Cancer Research, 2010. 8(1): p.

*chemoresistance through down-regulation of STAT3 and nuclear factor-κB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells.* Blood,

*and nuclear factor-κB activation and its in vitro and in vivo activity against multiple* 

*mitochondrial dysfunction and apoptosis in human multiple myeloma cells.* Blood, 2004.


[259] Tai, Y.T., et al., *Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma.* Cancer research, 2005. 65(13): p. 5898-5906. [260] Voorhees, P.M., et al., *Inhibition of interleukin-6 signaling with CNTO 328 enhances the* 

[261] Hunsucker, S.A., et al., *Blockade of interleukin-6 signalling with siltuximab enhances* 

[262] Voorhees, P.M., et al., *Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-*

[263] Todoerti, K., et al., *Pleiotropic anti-myeloma activity of ITF2357: Inhibition of interleukin-6* 

[264] Bisping, G., et al., *Targeting receptor kinases by a novel indolinone derivative in multiple* 

[265] Tassone, P., et al., *Combination therapy with interleukin-6 receptor superantagonist Sant7* 

[267] Wemeau, M., S. Balkaran, and X. Leleu, *Increased sensitivity to bortezomib after* 

[268] Rossi, J.F., et al., *Atacicept in relapsed/refractory multiple myeloma or active Waldenstrom's macroglobulinemia: a phase I study.* Br J Cancer, 0000. 101(7): p. 1051-1058. [269] Presta, L.G., et al., *Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal* 

[270] Lin, B., et al., *The vascular endothelial growth factor receptor tyrosine kinase inhibitor* 

[272] *Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.* Anti-Cancer Drug Design, 2000. 15: p. 29-41. [273] Ramakrishnan, V., et al., *Sorafenib, a dual Raf kinase/vascular endothelial growth factor* 

[274] Flier, J.S., P. Usher, and A.C. Moses, *Monoclonal antibody to the type I insulin-like growth* 

*marrow microenvironment.* Cancer research, 2002. 62(17): p. 5019-5026. [271] Hagedorn, M. and A. Bikfalvi, *Target molecules for anti-angiogenic therapy: from basic* 

*myeloma drugs.* Oncogene, 2010. 29(8): p. 1190-1202.

*in cytogenetically defined subgroups.* Blood, 2006. 107(5): p. 2079-2089.

*multiple myeloma.* Clinical Cancer Research, 2005. 11(11): p. 4251-4258. [266] Lamm, W., et al., *Bortezomib combined with rituximab and dexamethasone is an active* 

Research, 2007. 13(21): p. 6469-6478.

Haematology, 2011. 152(5): p. 579-592.

of Haematology, 2009. 145(4): p. 481-490.

Haematologica, 2011. 96(7): p. 1008-1014.

l'AMD3100, 2009. 15(3): p. 194-196.

57(20): p. 4593-4599.

110.

p. 260-269.

*activity of bortezomib in preclinical models of multiple myeloma.* Clinical Cancer

*melphalan cytotoxicity in preclinical models of multiple myeloma.* British Journal of

*clinical models of multiple myeloma to dexamethasone-mediated cell death.* British Journal

*receptor signaling and repression of miR-19a and miR-19b.* Haematologica, 2010. 95(2):

*myeloma: Abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis* 

*and dexamethasone induces antitumor effects in a novel SCID-hu in vivo model of human* 

*regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.*

*mobilization of multiple myeloma cells with the CXCR4 antagonist AMD3100.* Majoration de la sensibilité au bortézomib dans le myélome multiple en favorisant la migration des cellules tumorales dans le sang par un inhibiteur de CXCR4,

*Antibody for the Therapy of Solid Tumors and Other Disorders.* Cancer Research, 1997.

*PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone* 

*research to clinical trials.* Critical reviews in oncology/hematology, 2000. 34(2): p. 89-

*receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-*

*factor (IGF-I) receptor blocks IGF-I receptor-mediated DNA synthesis: clarification of the* 

*mitogenic mechanisms of IGF-I and insulin in human skin fibroblasts.* Proceedings of the National Academy of Sciences, 1986. 83(3): p. 664-668.


**6** 

James J. Driscoll

*Cincinnati, OH* 

*Bethesda, MD* 

*USA* 

**The SUMOylation Pathway as a Potential** 

**Therapeutic Target in Multiple Myeloma** 

*Division of Hematology and Oncology, Department of Internal Medicine University of Cincinnati Medical Center and Barrett Cancer Center* 

*Medical Oncology Branch, National Cancer Institute, National Institutes of Health* 

The Ubiquitin+Proteasome System (UPS) represents a successful anti-cancer strategy that has translated from preclinical studies to clinical development and significantly improved the survival of Multiple Myeloma (MM) patients (1). The proteasome is high molecular weight structure that contains multiple proteolytic sites and functions as the catalytic core of the UPS to degrade Ub~conjugated proteins (2-4). Inhibition of the proteasome's chymotryptic-like peptidase activity blocks the entire UPS and leads to selective tumor cell death. Bortezomib is the first proteasome inhibitor used in human clinical trials and treatment leads to a reduction in tumor burden in MM patients (5,6). However, cellular resistance to proteasome-based therapy generally results and reduces the efficacy. Resistance to proteasome inhibitors may result from altered expression of either proteasome or non-proteasome encoding genes. SUMOylation is a post-translational modification that attaches a **S**mall **U**biquitin-like **MO**difier to target proteins and, similar to Ub, may target proteins for proteasomal degradation. Gene expression profiling of MM patient samples indicated that bortezomib resistance may be achieved through induction of non-proteasome components. Importantly, certain effectors of the SUMOylation pathway were induced in the samples of MM patients that did not respond to bortezomib. A molecular-based, biologically-relevant supervised approach was used to identify a compendium of genes within the SUMO+UPS that were induced in MM patients and correlated with a decreased response to bortezomib. This molecular approach is relevant to a heterogeneous disease like MM where patients with similar clinical and pathologic features have vastly different genetic mutations responsible for disease and varying responses to therapies and clinical outcomes. The potential role of the SUMOylation pathway is only beginning to emerge, however, evidence indicates that SUMOylation is induced in myelomagenesis and also in

An aggresome is a proteinaceous inclusion body that forms when the cellular protein degradation machinery is impaired or overwhelmed and leads to an accumulation of proteins for disposal (7,8). Aggresome formation is thought to represent a cellular protective

**1. Introduction** 

bortezomib-resistant cells.

